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ABSTRACT
Exposure to light is known to produce changes within the human body. It has
demonstrated ability to produce changes in the circadian rhythm and the sleep wake cycle
and to change the production and secretion of melatonin and corticosteroids. The bulk of
research is related to the use of bright light therapy (BLT) for certain depressive
disorders. The literature does not provide a standard of care for BLT administration dose
or schedule. This study intended to identify any relationship between natural and ambient
light with a hospitalized patient’s mood and/or fatigue level. Further it aimed to relate
cumulative light levels with the hospitalized patient’s activity. In essence, it was an
investigation for potential correlation between light and the independent variables of
activity, mood and fatigue. If a correlation was identified, there may be strength to pursue
a trial utilizing BLT with a hospitalized patient population. Bone marrow transplant
(BMT) patients were selected because of documented issues with mood disturbance and
fatigue and because of the long hospital stay they experience during the transplant
process. BMT participants were monitored at two time points, Day 0 to Day 2 and Day 9
to Day 11, for activity and completed tools to measure fatigue and mood. Monitoring
devices captured light exposure and physical activity. Sample size was defined as 82
however 90 patients were enrolled. The study attrition rate was 33% yielding data for
only 60 participants. In the study results, a correlation between light and the dependent
variables of mood, fatigue and activity was not identified. There were correlations
xi

identified between activity, mood and fatigue. The study demonstrated that activity could
be a predictor of mood state and fatigue at D0-D2 and a predictor of mood state at D9D11. These findings may be better understood in a study with higher participant
retention.

xii

CHAPTER ONE
INTRODUCTION
Nightingale said, “Little as we know about the way in which we are affected by
form, by color and light, we do know this, that they have an actual physical affect”
(Nightingale, 1859/1960, p. 34). Nightingale identified elements in the environment that
promoted recovery. Elements such as light, color, sounds and surroundings continue to be
studied in an effort to understand their impact on a patient’s physical and mental
wellbeing. As the patient interacts with the surrounding environment, that environment
has the ability to produce negative or positive changes within the patient. While
Nightingale did not fully understand the science behind patient and environment
interactions, she believed that environment could have a dramatic effect on the patient.
There continues to be interest in creating healthcare spaces which maximize the
patient’s healing potential. Conceptually, the healing space may incorporate visual, tactile
and auditory elements which produce positive mental and/or physical responses in the
patient. A review of literature identifies components as positive distraction (including art,
music and audiovisual), a connection to nature (such as exposure to the outside, plants,
water and visual of nature) and exposure to natural or artificial light. Light as a
physiological and psychological stimulus is the most validated element demonstrating
varying levels of activity in its effect on the human body. Yet duration and intensity of
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light exposure have not been studied within general inpatient populations and light as a
therapy has only been investigated in a few patient populations.
Nightingale (1859) believed in the body’s need for light without fully
understanding how necessary it was for sustaining health. The usefulness and mystery of
light’s powers predates Ms. Nightingale by millennia. Ancient Egyptians utilized sunlight
as a healing power (Cocilova, 1999). Even with a long history of interest in the power of
light, we still know very little about its impact on the body’s function.
Light
Scientists continue to explore how light enters the body. Current knowledge does
not provide definitive information on how points of entry may influence light’s ability to
affect the body. Historically, the sole point of entry for light into the body was identified
as the retina. This point of entry is associated with light’s ability to stimulate the pineal
gland and the hypothalamus (Tamminga, 2006). This activity causes chemical and
hormonal changes while allowing light transmission to other parts of the body via
neuronal pathways (Moore, Heller, Wurtman, & Axelrod, 1967). It is now also known
that light can enter through the skin; research suggests that blood cells may serve to
transport absorbed light through the body to be used in protein and collagen synthesis
(Campbell & Murphy, 1998).
Light exposure changes the body's melatonin production (Lewy, Sack, & Singer,
1985) and causes changes in levels of norepinephrine, acetylcholine, cortisol, serotonin
and dopamine (Morita & Tokura, 1996). Exposure to higher levels of light suppresses the
body's production of melatonin (Lewy et al., 1985). An increase in adrenal gland
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secretion of corticosteroids is also associated with light exposure (Leproult, Colecchia,
L’Hermite-Baleriaux & Van Cauter, 2001). These chemical reactions promote the
rationale for light's ability to impact fatigue, the sleep-wake cycle and the circadian
rhythm; most likely these chemical reactions also create the relationship between light
and mood state.
The human body requires light to manufacture vitamin D. Historically vitamin D
deficiency was a product of poor diet and industrialization (Holick, 2008). While the
United States has foods fortified with vitamin D such as milk, orange juice, breads and
cereals, a natural dietary source of vitamin D is through oily fish. Even with many
fortified foods, the labeling of exact content is not fail proof due to varied analytic
methods for measurement and lack of standardization (Yetley, 2008). Achieving and
maintaining adequate serum levels of 25 hydroxyvitamin D at an acceptable level (>40
nmol/L) is difficult for those living in the northern latitudes (Peppone, Huston, Reid,
Rosier, Zakharia, et al, 2011).
Thomas and colleagues (1998) tested 290 patients admitted under a general
medical service and found that 57% were < 40nmol/L and 27% were < 20nmol/L, the
latter being a level that is considered severely vitamin D deficient. Tangpricha, Pearce,
Chen & Holick (2002) found 30% of their sample of 142 healthy young adults in Boston
to be considered vitamin D deficient at <40nmol/L when tested at the end of winter.
Short intervals of sunlight exposure can generate as much as 20,000 IU (Boyles,
2003) of vitamin D. But for populations living in the northern latitudes, substantial sun
exposure would be required during the summer months to sustain adequate serum levels
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throughout the winter months (Hanley & Davison, 2005; Mullin, Turnbull, Kines &
Mullin, 2009). As researchers learn more about how critical vitamin D is to health and
well being, there are significant connections being made between it and a protective
effect against breast, colon and prostate cancers (Robsahm, Tretti, Dahlback, & Moan,
2004; Peppone et al., 2011). These findings are in addition to the established importance
of vitamin D in bone and muscle health.
Low level interior light exposure coupled with society’s knowledge of the sun
exposure connection to skin cancer and acceleration of skin aging creates optimal
conditions to produce a widespread deficiency in healthy light exposure. As the
industrialization of manufacturing was believed to create a vitamin D deficiency in the
early 1900’s, today’s epidemic of vitamin D deficiency may be the result of the combined
effect of all of these conditions: longer periods in interior spaces and conscious avoidance
of sun exposure whether due to fear of skin cancer or premature skin aging. Light is an
essential element in a person’s health and wellbeing. But beyond the requirement of light
for adequate vitamin D levels, we are still learning about the role that light plays in other
physiological systems.
In attempting to delineate exact mechanisms for light's ability to impact certain
symptoms, one must consider a common organ which is stimulated by light. The
hypothalamus is a portion of the brain which is connected to the nervous system as well
as having indirect links to the endocrine system. It is a focal locus of control for such
physiologic responses as fatigue, sleep and the circadian rhythm (Hauw, Hausser-Hauw,
Girolami, Hasboun & Seilhean, 2011). While the biochemistry is not definitive, the use
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of light in certain depressive disorders is also based on the ability of light to impact
biochemical operants in the brain including the hypothalamus (Martensson, Petterson,
Berlund & Ekselius, 2015). When focusing on the patient population that suffers from
fatigue, mood disturbance and sleep-wake disruption, the patient undergoing peripheral
blood stem cell transplant (PBSCT) is a prime example (Bevans, Mitchell, & Marden,
2008). To postulate that light could impact the patient undergoing PBSCT who is
experiencing this triad of symptoms is not far reaching but appears to be a valid postulate
worth investigation.
Light as a therapy. In its own basic unit, light is measured in units of candle
lighting. One foot-candle describes the illumination of a surface by one candle placed one
foot away from the object it intends to illuminate. The term, foot-candle, is rooted in the
history of light measurement but the brightness of a light source in industry is measured
in lux (Cocilovo, 1999). Lux, as a unit of measurement for the luminance of a light
source is correlated with foot candle; one foot candle equals 10.764 lux. A person sitting
out on a sunny, summer day is exposed to well over 2,000 lux, yet typical lighting
provided in most interior public spaces ranges only from 300 to 500 lux or lower.
Knowing the impact light has on biochemical functions in the body, lower light exposure
may tend to have a negative impact on those functions.
Truly the focus of light as a therapy centers on the use of bright light therapy
(BLT) and its application is very focused on seasonal affective disorder type depression
(SAD), with emerging research on BLT application in neurological conditions such as
dementia, Parkinson's Disease and Alzheimer's Disease (Ancoli-Israel, et al. 2003;
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Hickman et al. 2007; Paus, Schmitz-Hubsch, Willner, Vogel, Klockgether & Abele,
2007). There is a void of research on the effect of natural and ambient light on the
hospitalized patient. It can be assumed that light exposure to the inpatient environment is
similar to what a person experiences in any interior space. Knowing that the intensity of
light in interior spaces can be one-tenth of the exposure a person receives while outside
on a sunny day, a prolonged hospitalization has the potential to seriously impact those
physiological processes which are stimulated by exposure to light.
Light has shown an ability to effectively minimize fatigue, modulate mood states,
enhance cognitive functioning and treat sleep-wake cycle disruption in select patient
populations such as institutionalized Alzheimer’s patients and elderly patients in
residential settings as well as hospitalized psychiatric patients (Benedetti, Colomb,
Barbini, Campori, & Smeraldi, 2001; Chong, 2013; Dowling, Graf, Hubbard &
Luxenburg, 2007; Fetveit-Skjerve & Bjorvath, 2003; Hickman et al. 2007; Paus et al.
2007; Royer, Ballentine, Eslinger, Houser, Mistrick et al. 2012) . It may hold some
promise as a treatment option in affecting cancer related fatigue, associated sleep
disruption and mood distress. The use of light as a therapy has been applied to limited
numbers of breast and esophageal cancer patient populations (Liu et al. 2005; Neikrug et
al. 2012; Ono et al 2001). In order to investigate the use of BLT and relate these levels to
selected outcomes, there must be some foundational work done to explain what light
levels exist during the inpatient experiences. In baseline assessment of light levels,
gaining knowledge about possible relations between light levels and common symptoms
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experienced by the hospitalized cancer patient may be possible. Higher light levels
should correlate with lower levels of fatigue and more positive mood states.
Bone marrow transplant. Bone marrow transplantation is a generalized heading
for several procedures which intend to support or replace a person's own immune system.
The immunity we possess is generated from the bone marrow. The transplant procedure
includes acquiring the hematopoietic stem cells from bone marrow, peripheral blood, and
umbilical cord blood (National Marrow Donor Program, 2016). The cells used in the
transplant can be obtained from the patient intended for treatment (autologous) or from a
related or a matched unrelated donor (allogeneic). Statistically there have been over
55,000 peripheral blood stem cell or marrow transplants in the U.S. since 2013 (National
Marrow Donor Program, 2016). It remains a treatment with many risks and possibly high
mortality dependent on the underlying disease and other patient characteristics.
Used primarily for the treatment of leukemias and lymphomas, bone marrow
transplant is also being used for precursor conditions for hematologic malignancies,
inherited blood and immune system disorders, certain autoimmune disorders and solid
tumor cancers. Its application continues to grow as the science of tissue transplantation
continues to develop. Due to potential life threatening toxicities associated with the
procedure, stem cell or bone marrow transplant is typically performed in large academic
medical center settings. The majority of transplant centers in the U.S. are part of the
National Marrow Donor Program which is a non-profit, government supported registry
that also promotes donorship to become part of the database to expand matching potential
for patients.
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The transplant process begins with finding an acceptable match for the patient if
the condition being treated cannot use the patient's own peripheral blood stem cells
(PBSC). In autologous transplant, the patient undergoes plasmapheresis to harvest cells.
Once PBSCs are identified, the patient undergoes a therapy referred to as a conditioning
regimen. This is typically a combination of cytotoxic medications which eliminate the
malignant or abnormal cells as well as the bone marrow's ability to produce component
cells for immunity. The treatment regimen may also involve radiation therapy. It is a very
aggressive treatment regimen which renders the patient with minimal or no immunity
potential. Along with a myriad of side effects, patients must remain protected from
contact with any possible source of infection. The normal bacteria and viruses found
routinely in the environment, which do not impact an individual with a functioning
immune system could potentially infect and kill a patient with an incompetent immune
system. The infusion of stem cells or bone marrow occurs at the completion of this
regimen and the patient is monitored closely for 14 to 28 days while blood counts
recover. During this period, patients are watched for complications which can include
infection and acute graft versus host disease (GVHD). The time period following
reinfusion presents a significant risk for morbidity and mortality. While the average
length of hospital stay is 22 days, many patients may spend 100 days or more recovering
from the treatment, awaiting cell engraftment (National Marrow Donor Program, 2016).
The national average of patients alive at 1 year post bone marrow transplant lies around
50% but is dependent on the type of transplant, underlying malignancy and patient health
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status prior to transplant (National Marrow Donor Program, 2016; Dartmouth-Hitchcock,
2007).
With the PBSCT, a patient can experience an inpatient stay that far exceeds
inpatient stays of other patients receiving active cancer treatment. Because of the ablation
of the patient’s own bone marrow, infection is the greatest risk for the patient during the
period post stem cell infusion prior to recovery of the bone marrow. The procedure
requires reverse isolation/negative pressure rooms which limit exposure to friends and
family. While many patients receiving autologous transplants are now able to receive
much of their treatment on an outpatient basis, the allogeneic transplant carries more
toxicities including graft versus host disease (GVHD) and a greater risk of mortality
leading many of these patients to remain in the hospital for prolonged periods (Robin et
al., 2009). GVHD is a condition where the transplanted cells launch an immune response
against the patient and it can be an acute and/or chronic condition (Bevans, Mitchell &
Marden, 2008). Because the patient must protect themselves from potential infection,
many will remain inside rather than outside which will limit the level of light exposure to
normal interior light levels of 300-500 lux. The consequence of this deprivation of
moderate to high levels of light in this patient population has never been studied.
There are three symptoms that this patient population frequently experiences:
fatigue, mood disturbance and sleep-wake disruption (Gaston-Johansson, Fall-Dickson,
Bakos & Kennedy, 1999; Trask, Paterson, Riba, Brines, Griffith et al. 2002; So, Dodgson
& Tai, 2003; Grulke, Bailer, Kachele & Bunjes, 2005; Hacker et al, 2006; Carlson,
Smith, Russel, Fibich & Whittaker, 2006; Bevan et al.2008). Of interest, these symptoms
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have been minimized or abated with light application in other patient populations. These
patient populations include the elderly with and without neurologic decline or deficiency
and patients with specific types of depressive conditions. These conditions and light's
impact on them will be discussed in greater detail in the following chapter. Light levels
have not been studied in the patient undergoing a PBSCT.
Fatigue. The toxicities of PBSCT as a treatment affetsaoct almost every
physiologic system in the patient; however, one of the most common complaints in
patients with any cancer diagnosis is that of fatigue. Fatigue associated with cancer and
cancer treatment is a well-documented symptom, however its etiology has yet to be
determined. There continue to be efforts toward defining characteristics that differentiate
between general fatigue and cancer related fatigue (Stone & Minton, 2008). The most
substantial qualifier is that cancer related fatigue is not directly related to exertion and
does not abate with rest (Mock, Frangakis, Davidson, Ropke, et. al. 2005). Cancer related
fatigue has been documented as beginning prior to treatment initiation, to exist during
active treatment and to continue for months to years after treatment has been completed.
Cancer related fatigue does not appear to discriminate between cancer cell types or
treatment regimens. While there is emerging research on cancer related fatigue as a
separate and distinct entity, the present research will focus on the general concept of
fatigue and how it is experienced in the patient undergoing PBSCT for a malignancy.
Research investigating fatigue in PBSCT was often associated with the
measurement of quality of life. Certainly fatigue is a symptom during and after the
transplant process that impacts an individual's quality of life. Studies have shown that
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fatigue is a predominant symptom not only during the first 100 days but may continue to
affect the patient's functioning for a year post transplant (Winer. et. al., 1999, Watson.
et.al., 2004; Bevans, Mitchell & Marden, 2008). Dependent on the study, moderate
fatigue is reported in up to 60% of these patients at year one.
Within the current literature, there are several approaches being studied to
decrease the fatigue associated with cancer treatment and post therapy. These include
exercise including yoga (Banasik, Williams, Haberman, Blank, & Bendel, 2011; Taso,
Lin, Lin, Chen, Huang, et al.2014), cognitive behavioral therapy (Berger, et al. 2009),
and pharmacologic interventions (Yavuzsen, et al. 2009). The bulk of the research has
been performed using exercise during and after treatment for cancer to mitigate fatigue.
Light exposure or BLT was only found in one study involving BMT patients
(Redd, Valdimarsdottir, Wu, Winkel, Byrne et al. 2014) so there is very limited
experience. Studies with breast cancer patients, fatigue and light exposure or BLT are
found with greater frequency (Ancoli-Israel, Rissling, Neikrug, Trofimenko, Natarajan et
al. 2012; Liu, et al. 2005; Redd et al. 2014)). In these research studies, a negative
relationship was identified between the duration of light exposure and the patients’
reports of fatigue. Patients who were exposed to higher levels of natural light, ambient
light or BLT reported lower fatigue scores. Sun and colleagues (2014) studied light
exposure, fatigue, depression and sleep quality in cancer patients receiving outpatient
chemotherapy. Calculating the number of minutes that patients received > 1000 lux,
researchers found patients who received greater light exposure over time reported better
sleep quality, less fatigue and less depression (r = -0.61, p < 0.001; r = -0.18, p = 0.03; r =
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-0.18, p – 0.02 respectively). An additional study was found using BLT with post
operative esophagectomy due to cancer (Ono, Taguchi, Kido, Fujino, & Doki, 2001);
however this study centered on BLT reducing the amount of cognitive issues occurring in
a postoperative ICU setting.
One hypothesis underlying the use of exercise to combat cancer related fatigue
also has ties to the hypothalamus. In general, lack of activity and de-conditioning which
often accompanies cancer treatment promotes fatigue; as treatment continues, fatigue also
increases (Wilson, Jacobsen, & Fields, 2005). This can be perceived as a stressor to the
mind-body homeostasis. One of the body's main neuroendocrine response to stress is
activation of the hypothalamic-pituitary-adrenocortical axis, which results in the secretion
of adrenal corticosteroids. Researchers have demonstrated chronic psychosocial stress
leads to a dysregulation of the hypothalamus-pituitary-adrenal axis which predisposes the
body to increased inflammation (Miller, Ancoli-Israel, Bower, Capuron, & Irwin, 2008).
Inflammatory molecules can signal the brain and engender behavioral symptoms like
fatigue (Dantzer, O’Connor, Freund, Johnson & Kelley, 2008; Miller, Ancoli-Israel,
Bower, Capuron, & Irwin, 2008). As in the application of light, there is a trigger which
promotes activity by the hypothalamus.
This hypothesis provides credible rationale given the knowledge that cancer
related fatigue is not definitively connected to treatment initiation. Its etiology may be
related to this hypothalamic stimulation and subsequent secretions by the pituitary and
pineal glands. The stimulation of the inflammatory response would occur even prior to
the actual diagnosing of the cancer. This could give reason for fatigue's presence before
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treatment has been initiated. It could also be the reason why fatigue can remain with the
patient long after the treatment has been completed. Ongoing inflammation at a
subclinical level may be the etiology for the continued fatigue.
Yoga has been used to modulate the effects of fatigue with breast cancer survivors
and patients receiving active treatment (Banasik et al. 2011; Bower, Greendale,
Crosswell, Garet, Sternlich, et al. 2014; Danaher-Hacker, Ferrans, Verlen, Ravandi, van
Besien et al, 2006; Taso, Lin, Lin, Cheng, Huang, et al. 2014). Yoga as an intervention is
focused more on the mind body connection and not aerobic activity to combat fatigue.
These studies typically are small and often times do not show clear direction in the
findings. The available research suggests that motivated patients who stayed within the
program requirements benefited (Danaher-Hacker et. al. 2006; Bower et al. 2014;
Moadel, 2007; Taso et al. 2014). Success in some of these experiments may only
translate to preventing the level of fatigue from increasing as treatment progresses versus
providing an actual decline in fatigue. Taso and colleagues (2014) were able to show a
reduction in fatigue with an eight week yoga program when compared to a control group
which received standard care; this study did demonstrate any impact on depression or
anxiety. Research performed by Bower and colleagues (2014) utilized yoga in breast
cancer survivors and through a twelve week course identified reduced activity of a proinflammatory factor, increased activity of the anti-inflammatory glucocorticoid receptor,
and changes in the soluble tumor necrosis factor receptor, a marker for TNF activity. This
research demonstrated that there were significant differences in the plasma levels in
biochemical elements in the body associated with yoga as an intervention. In other types
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of cancers where primarily outpatient therapy is the course, attrition in exercise studies
has been high (Andersen, Vinther, Poulsen & Mellemgaard, 2011; Wilson et. al. 2005).
There have been reported abnormalities in the circadian rhythm and cortisol levels
in breast cancer investigations and this again suggests a link to dysregulation of the
hypothalamus, the pineal and the pituitary glands (Sephton & Spiegel, 200; Stone,
Schwartz, Smyth, Kirschbaum, Cohen et. al. 2001). The researchers do not propose the
rationale for a connection between yoga or exercise and fatigue, however it is suggestive
of a psychoneuroimmunology connection. This connection does promote the concept of
mind-body collaboration but the associated biochemical activities are not well defined.
A longitudinal study investigating symptoms post BMT for multiple myeloma
patients demonstrated that the most severe long term side effects such as fatigue and
muscle weakness remained present in 35% of patients (Wang, Shi, Williams, Shah,
Mendoza, et al, 2015). Inflammatory marker essays performed on the participants (N =
55) resulted in high symptom patients demonstrating a significantly elevated baseline
tumor necrosis factor-alpha (p = 0.014). This type of ongoing research will hopefully lead
to a clearer relationship between biochemical changes, inflammation and fatigue.
Mood disturbance. The transplant recipient has frequently undergone multiple
failed treatments or relapses and may be receiving a PBSCT as a final treatment option.
Even if the patient is receiving a transplant early in their diagnosis, mood disturbances
are not uncommon and are documented in a variety of cancer conditions (Trask et al.,
2002; Guelke, Larbig, Kachele & Bailer, 2008). Depression and other mood disturbances
can present in this patient population before treatment begins and frequently transplant
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programs have psychological support and treatment for this throughout the transplant
experience. Many patients are placed on one or more antidepressants or antianxiety
medications prior to, during and post transplant.
In addition to being difficult on the body, the transplant process can be very
frightening and overwhelming. The mainstay of treatment for these patients has been
psychological therapy and medications. While BLT has been used in non-cancer patient
populations with mood disturbances such as SAD and with a few neurological conditions,
research on interaction between light and mood disturbances in the patient receiving
PBSCT is limited. Occupational studies have shown worker attitudes about their work are
positively correlated with higher exposure to natural light (Leather, Pyrgas, Beale &
Lawrence, 1998). Because patients receiving PBSCT undergo a prolonged period of
restriction from the outside, their exposure to natural light would be expected to decline
during treatment and recovery. Increased exposure to natural and ambient light may not
prove to resolve mood disturbances in this patient population, however it could be
beneficial to establish relevancy for BLT use as an adjuvant treatment modality.
Psychological distress for the patient receiving transplant can frequently begin in
the pre-transplant period. It is not only the magnitude of the treatment that can distress
the patient, some patients find the isolation requirements overwhelming (Sasaki, et.al.
2000). Emotional distress and anxiety are issues that are addressed throughout the
transplant process.
There are supporting studies linking a relationship between fatigue and
psychological distress (Gaston-Johansson et al. 1999; Molassiotis, 1999). More research
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has been performed with patients receiving allogeneic transplants as their recovery is
typically filled with greater challenges than their autologous counterparts. Toxicities are
more severe and isolation tends to be much more rigorous in allogeneic transplants.
As research has demonstrated that BLT effectively treats sleep-wake cycle
disruption in select patient populations (Benedetti et al. 2001; Chong et al. 2013;
Hickman et al. 2007), light therapy may hold some promise as a treatment option in the
cancer related fatigue and associated sleep disruption. BLT has been beneficial in helping
non-SAD patients with mood disturbances. Selecting patients receiving bone marrow
transplantation will provide for the examination of light levels during a longer inpatient
stay or a more intensive outpatient treatment regimen.
Triad of symptoms and connection to light. While it is accepted that stress on
the body triggers a response from the hypothalamus-pituitary axis, the connection or
interaction of light with this response has not been investigated. The ability of light to
lessen fatigue, decrease depression, and/or enhance sleep-wake cycle may occur through
alteration of the hypothalamic function. In fact, the one study performed by Liu and
colleagues (2005) did find a significant negative relationship between fatigue and light.
Jeste (et al., 2013) found BLT in breast cancer patients receiving treatment resulted in
maintenance of quality of life scores and depression scores. Redd and colleagues (2014)
study of post cancer treatment patients with CRF correlated BLT with decreased fatigue
over time but excluded depression as a predictor in these patients. It is within this
connection that interjects the question: what is light's relationship with these three vexing
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symptoms of fatigue, mood disturbance, and poor sleep in this particular patient
population?
Significance to Nursing
The goal for nursing has always been to improve the patient’s outcome while
enhancing the patient experience. As a science and a practice, nursing has continued to
focus on the entire person rather than the sum of the parts. The domain of nursing is to
provide interventions that are central to the patient’s recovery while also coordinating
with the medical interventions. Investigation of ambient and natural light as a noninvasive adjunct to patient treatment appears well within the scope of nursing practice
and in fact could render an application that could be nurse driven to benefit patients.
The patient undergoing PBSCT is engaged in a fight for survival in many cases.
Whether the transplant is an initial therapy or a salvage therapy, it is a difficult process
with many side effects which can be lethal. The idea of something as benign as light to
enhance the patient’s experience and potentially impact their ability to withstand the
hardships of therapy seems almost naïve but it is no more simplistic than Nightingale
opening the windows to let fresh, clean air circulate in the nursing ward. It is not the
belief that light can serve as a lifesaving therapy which will impact survival. But the
application of light may provide a better patient experience as an intervention at no cost
to the patient. The cost-benefit ratio could be astronomical if light’s application can help
the patient weather the treatment regimen by facilitating a better mental perspective and
physical functioning,
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Purpose and Hypotheses
The purpose of this study was to test the hypothesis that light levels have a
relationship to the levels of fatigue and mood a patient experiences while undergoing a
bone marrow transplant. In addition, it meant to establish baseline light levels during the
transplant process that a patient is exposed to and determine the relationship that exists
between light levels and the common complaints of fatigue, mood disturbance, and
activity intolerance. The findings from this investigation are meant to identify if there are
opportunities to employ the use of BLT with these patients during their prolonged
hospital stay.
Research Question
What is the relationship between light levels and physical and psychological state
in the patient undergoing a bone marrow transplant procedure?
Aim 1. Establish the relationship between, natural and ambient light exposure
with fatigue and mood in the bone marrow transplant patient.
Hypothesis 1. There is a significant relationship between the level of light
exposure and the patient’s report of fatigue and mood.
Aim 2. Establish the relationship between the level of light exposure and a bone
marrow transplant patient’s physical activity during transplant hospitalization.
Hypothesis 2. There is a significant relationship between the level of light
exposure and the patient’s physical activity during transplant hospitalization.
Aim 3. Establish the relationship between the level of light exposure and fatigue
at two time points in the bone marrow transplant process.
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Hypothesis 3. There is a significant relationship between cumulative light
exposure and the patient’s perception of fatigue between pre-transplant and posttransplant day 11.
Summary
Light is part of the natural world and has been shown to interact with the human
body. It has demonstrated benefit to specific patient populations in decreasing depressive
symptoms and the regulation of sleep-wake cycles. Small studies are suggesting benefits
to neurologic symptoms in Alzheimer’s disease (Ancoli-Israel et al.2003), dementia (Graf
et al. 2001; Hickman et al. 2007), and Parkinson’s disease (Paus et al. 2007). While we
know that light does affect the human body, the research on light as a therapy is limited
for conditions such as cancer. The following chapter will provide foundational theoretical
frameworks that support the concept of interaction between the human body and
environmental light. The constructs found in Nightingale’s (1859) early identification
that the environment impacts the health- illness state in the human and Martha Rogers’
Science of the Unitary Human Beings (Rogers, 1980) will be discussed. Chapter 2 will
also iterate the state of knowledge regarding the interaction between light and the human
body and any relationship between fatigue and mood distress and light in the patient
undergoing PBSCT.

CHAPTER TWO
LITERATURE REVIEW
The study of light has relevance to the conceptual nursing model of Florence
Nightingale (1859/1960). The study of light as an intervention also can be supported
through the theory of Martha Rogers (1980): The Science of Unitary Human Beings. The
concept of the human continuously interacting with their environment is central to
understanding how light can impact change in the human. Central to these practice modes
is the concern for human and environment interaction striving to regain healthful balance.
This chapter will explore the use of these nursing theories as well as the supporting
literature which provides practical application of light to benefit various patient
populations
Theoretical Frameworks
Florence Nightingale. Nursing has always been concerned with creating an
environment where the patient can recover and heal. The idea of the environment
contributing or countering the patient’s illness was part of Florence Nightingale’s
strategy in caring for the sick. Certainly in her work “Notes on Nursing: What it is and
what it is not” (Nightingale, 1859/1960), she identified elements that were important in
regaining health and well-being. These included clean air and water, efficient drainage,
environmental cleanliness along with adequate ventilation and light (Nightingale, 1859/
1960). She went beyond the basics to the esthetics when she promoted the use of light
20
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and windows and the reduction of noise as environmental manipulations to aid in the
patient’s recovery. Nightingale believed that a dark house was an unhealthy house and
that without sunlight, the mind and body degenerated (Nightingale, 1859/1960).
Nightingale was ahead of her time in her identification that oil based paint on
interior walls was sub-optimal due to the odor; this is still relevant today. Volatile organic
compounds (VOC) are a byproduct of certain paint types that can have atmospheric
photochemical reactions (EPA, 2010). VOCs can cause irritation to the eyes, nose and
throat; in its more potent phase, it can cause organ damage with continued exposure over
time. We see more paint companies producing low VOC paint to prevent what today is
termed “off gassing”. Finally, Ms. Nightingale appreciated the value of pleasing interior
spaces saying “color and form means recovery” (Nightingale, 1859, p. 33). Only through
the use and application of light can one see or appreciate the color spectrum.
Nightingale wrote of being able to smell small pox growing in closed rooms or in
overcrowded nursing wards (Nightingale, 1859/1960). It was her belief that the
surrounding environment possessed a wealth of variables that intervened in the human
condition and those variables affected the success of nursing’s interventions with the
patient (Robinson & Kish, 2001). Her approach focused on the physical spaces with less
emphasis on psychosocial interventions. Nightingale’s concepts of the individual, the
environment, health/illness and nursing were all in play, interacting and affecting one
another (Gillette, 1996).
The relationship between fresh air and light with health are as central to
Nightingale’s approach as that of cleanliness. Open windows in sick rooms meant fresh
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air and light reached the patient. Those natural elements were important in Nightingale’s
approach to recovery but were less accessible in her environment. Conditions in the
“healthcare environment” often impeded the patient’s return to a healthy state. Sanitation
was not generally addressed in public areas. Cities were often dark and dirty with only
the wealthy being able to escape to the country.
Nightingale’s worldview of nursing also delineated the roles of medicine and
nursing with a great distinction. As medicine practiced from a framework of diagnosis
and treatment, the nurse’s goal and mission were to create an environment for the patient
that would serve as an adjunct to the internal healing processes of the human body
(Nightingale, 1859/1960; Tschirch, 1997). There was an overarching perspective that the
body must be interacting with an environment that was conducive to healing.
Nightingale’s framework for nursing included the concept of caring for the whole
person – mind, body and spirit. The patient was not reducible to a diagnosis. This
perspective is evident in more contemporary nursing theories and is a cornerstone for the
practice of nursing. Martha Rogers carried this theme of patient and environment
interaction to a refined framework for nursing practice. Rogers, similar to Nightingale,
believed that nursing’s charge was to promote health, using a consistent approach that did
not include adaptation to illness.
Roger’s Science of Unitary Human Beings
Nursing is typically not the designer of health care spaces yet nursing is charged
with defining methods that positively impact the human health and wellness experience.
As stated by Rogers (1970, p. 86) “nursing aims to assist people in achieving their
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maximum health potential.” This mission encompasses every location and condition
associated with the patient because the person is central to everything that nursing does.
Similar to Nightingale’s framework, Rogers’ Science of Unitary Human Beings
(Rogers, 1970) considers the whole person as continuously interacting with the
environment and not as a diagnosis or an illness. Rogers’ perspective encompasses the
universe as multiple open systems with an importance on mutual processes between and
among those systems. Change never ceases and supports continuous innovations and
diversity (Lewandowski, 2004). The person and environment are energy fields that
coexist. The concept of wholeness means that parts of the person cannot be addressed in
isolation to describe or predict characteristics or responses; the whole cannot be reduced
into parts. Rogers defines the person as “an irreducible, indivisible, pandimensional
energy field identified by pattern and manifesting characteristics that are specific to the
whole and cannot be predicted from the parts” (Rogers, 1992, p. 43). Each person is
characterized by a particular wave pattern.
The basic concepts for Rogers’ (1980) theory include the unitary human being,
the environment and homeodynamic principles. Homeodynamic principles provide a way
of perceiving unitary human beings. Each entity, whether human or environmental, has
an energy field which varies in intensity, density and extent (Farren, 2009). There is
openness between the human field and the environmental field with no boundaries and a
constant exchange between the two. This describes a component of homeodynamics
Rogers termed integrality (Biley, 1992). Resonancy, the second component of
homeodynamics describes the directional changes occurring between the energy fields of
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the person and the environment. Lastly, helicy describes the rhythmicity in life formation
and the constant interaction between energy fields. Each of the energy fields has pattern
which distinguishes it from another and gives identity to the field. Pan-dimensionality is a
key concept of the theory-the human is multidimensional manifesting characteristics
which are specific to that human as a whole (Rogers, 1970).
Rogers rejected the concept of adaptation to illness (Lewandowski, 2004). Illness
is not seen as something external to the human therefore human change is not through
adaptive measures (Malinski, 1994). Illness can be viewed as an internal stimulus which
will induce the human to develop to an increasingly diverse pattern. This diverse pattern
changes through mutual processes evolving to a higher frequency of wave patterns
(Rogers, 1992). The focus has always been on the wholeness of the person and the
rejection of causality (Wright, 2007). Rogers’ perspective is essential to the present
research in that she believed that her conceptual model would provide a platform for the
human experiences that one cannot understand; there is still much mystery in how we are
affected by our environment and conversely, how we impact our environment (Smith,
2007).
The theory posits that the person’s energy field can change in its configuration.
Rogers called this variation of energy fields ‘patterning’. Patterning represents how the
human and environment are able to interact which drives growth in the human energy
field. (Bateson, 1979; Rogers, 1990). The goal is for the pattern to change and mobilize
toward change. As the human field diversifies, change can occur more rapidly and within
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the Rogerian perspective the more complex the field, the more rapid change can occur
(Rogers, 1980; Hastings-Tolsma, 2006).
Rogers viewed the patient evolving as an active participant in their health care.
Patients are challenged with an illness which they need to understand. If they are able to
understand the illness, they can also understand what they must do in order to affect the
outcome; hence the patient moves toward positive outcomes and mitigates the chance of
negative outcomes (Malinski, 2007). Since Rogers saw the patient as continually
interacting with their environment, they are able to embrace the knowledge of those
interactions. She also believed that non-medical interventions had a role to play, viewing
these as adjuvants which could again increase the probability toward positive outcomes.
This perspective is quite in line with the idea of light interaction impacting the person in a
positive way.
Walling (2006) applied Rogers’ theory to the delivery of acupuncture for a patient
with chronic pain. Acupuncture is a method used to reduce the patient’s pain through
manipulation of the environmental energy field. The application of acupuncture allows
for the manipulation of the environment energy field as it interacts with the patient’s
energy field. Pathophysiologic processes can be seen as expressions of the life process in
the same manner as health. Disease can be utilized as information for the patient to
understand and get in touch with one's own pattern.
The environment is an energy field which continuously interacts with the human
energy field. It is inconceivable that the two energy fields are not always interacting.
While it is not always known whether the environment has a positive or negative
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interaction with the human, a foundation of the theory is that there is interaction between
the two. This perspective creates a rationale for why psychoneuroimmunology is
plausible. It is through the mind’s perception which connects to the individual’s
neurological, immunological and endocrine systems. This same relationship supports the
idea that light has the ability to maneuver alterations in the human energy field. Just as
Walling (2006) captured acupuncture operating external to the body (within the
environmental energy field), yet impacting the human energy field, light should have the
same ability. Lewandowski (2004) utilized Rogers’ theory in the perspective of chronic
pain interacting with the human energy field while the patient utilizes guided imagery
under the same premise. The impact of pain is manifested in the mind-body-spirit
interaction with the environment.
Acupuncture is an applied intervention and its application to alter the human
experience may be viewed as similar to that of exposure to light. Both are external
applications which can manipulate the internal body; both manipulate in ways which are
not fully understood. The human energy field is continually interacting with the
environmental energy field. Light is present in that environmental energy field and has
the ability through that interaction to create change in the human energy field. The
interaction has the ability to alter homeostasis in the human. The goal is always focused
on enhancing the communication and interaction between the energy fields that exist with
the human and the environment.
It is nursing’s charge as well as its passion to explore methods which contribute to
that achievement of wellness (Wright, 2007). From a Rogerian perspective, nursing must
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form mutual care partnerships with patients while developing, advocating, and applying
creative use of non-invasive modalities to assist the patient toward greater well-being
(Malinski, 2007). The use of an innovative technique such as BLT is within that same
vein. It can be part of nursing’s professional domain and mission to use creative
interventions to benefit patients (Malinski, 2007). The illness that a patient experiences
may prevent the human energy field from evolving to a shorter wave and higher
frequency pattern. The evolution to a more diverse patterning would manifest as a greater
sense of well-being (Lewandowski, 2004). Utilization of Rogers’ world view can only
assist nursing’s evolution as a science with the perpetual goal of extending and
transforming our understanding of the patient and his/her environment (Malinski, 2008).
The concept of wellbeing is an intangible. However, none of us would deny its
existence. Science has attempted to measure it using subjective tools. But within the
perspective of Rogers, it may remain an intangible and something that is innately within
the individual’s energy field. We know it exists in the feelings we get when viewing a
beautiful sunset or the distress we sense without knowing exactly what is wrong. It
cannot be separated from the human and is a part of him/her. Rogers reminds us that the
nurse is part of the experience; the observation of phenomena must include the observer
while the observer also becomes part of the experience (Armstrong & Kelly, 1995). The
Science of Unitary Human Beings can be applied to the current study of light interaction
with the human. The following theoretical assumptions from Roger’s (1980) theory are
essential to laying the framework for the proposed study:
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1. A human is a unified energy field which is more than the sum of its parts
2. A human and their environment continuously, simultaneously and mutually
exchanging energy with each other
3. The human changes by way of patterning when light is integrated into the
environmental energy field.
4. The patterning results in an exchange process which brings the human pattern
to a higher and varied frequency.
5. The human energy field (person) is identified through pattern and frequency
which can be impacted positively by changes in the environmental energy
field such as light.
Definitions
Unitary human being. A four dimensional energy field that cannot be reduced or
divided; it has characteristics that are part of the whole however the energy field can’t be
described by parts but only through the whole; one cannot summarize the parts to
describe the whole (Rogers, 1970) .
Environment. An energy field which is identified by unique pattern and cannot
be reduced to parts; it is an energy field that is integral with the human field (Rogers,
1970.
Energy field. A fundamental unit of both the living and non-living, it
continuously varies in intensity, density and extent. The human and the environment are
fields as energy fields which are irreducible wholes (Rogers, 1990)
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Openess. Energy fields constantly exchange energy with one another without
boundaries or barriers that would inhibit that flow of energy between fields (Rogers,
1970)
Pattern. It is the distinguishing characteristics of the energy field perceived as
single waves; it is the abstraction that gives the field identity and uniqueness; pattern can
change (Rogers, 1992)
Pan dimensionality. It is the domain the energy fields exist in and has no spatial
or temporal attributes; parameters are arbitrary which humans use in language to describe
events; the present is relative (Rogers, 1970)
Resonancy. The ordered arrangement of rhythm characterizing human and
environmental fields; it undergoes continuous and dynamic change as the human and
environmental fields interact (Rogers, 1990).
Helicy. The continuous, non-linear evolution of energy fields which are
manifested by non-repeating rhythmicities (Rogers, 1990).
Integrality. Embodies the mutual and continuous relationship between human
and environmental energy fields; there is a continuous re-patterning of these fields; the
fields are one and integrated yet unique (Rogers, 1990).
This research will test the theory, Science of Unitary Human Beings (1970) in the
relationship between the human and environment energy fields and patterning. Fatigue as
a pattern in the energy field can serve as a disruption in the person-environmental field
process. The energy field will continuously re-pattern in response to interaction with
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internal and external waves. Pattern embodies the relationship between human and
environment energy fields
It is within the framework of Rogers’ (1980) theory that the human energy field
may evolve through its continuous interaction with the environmental energy field. As it
evolves, re-patterning occurs through this constant interaction. Healing is viewed as a
rebalancing of the patterning. Light as a rhythmic wave of energy interacts with the
human providing an opportunity for re-patterning of the human energy field. Light
creates a change to the source of the energy imbalance, fatigue. In illness, multiple
factors will cause a disruption and/or blocking of the pattern.
The Science of Unitary Beings theory (Rogers, 1980) places nursing in the role of
effecting re-patterning aimed at promoting harmonious interaction between the fields.
Nursing can employ interventions such as light, sound and colors to promote the
harmonious interaction which in turn will impact the interaction between the human
energy field and the environmental energy field. Patterning provides the energy field with
its individual character, however it is not observable. The manifestation of patterning of
the energy field is present in the change process. Changes occur within the interaction
between the person and the environment (Rogers, 1970)
Within the theory, healing is viewed as the energy field’s progress toward
harmony within itself while illness is the blocking, disrupting and unbalancing of the
movement toward harmony within the energy field (Rogers, 1970). Rogers postulated
nursing interventions impact the energy field moving the human-environmental
patterning to a higher frequency. With the application of light, the nurse becomes an
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integral participant in altering the energy pattern of the patient. The nurse also lays the
foundation for the patient to become an active participant through education. The patient
has the knowledge to develop an expectation that light amount and duration of exposure
may decrease the level of fatigue they perceive. Nursing can help patients become aware
of their pattern within their own sense of well-being while encouraging the patient toward
changing their own pattern through the use of choice, the freedom to act and become
more aware of the interaction of self and environment (Rogers, 1970).
A person can experience fatigue as an energy field disturbance. In the present
study, fatigue is viewed as a manifestation of the process of patterning. A patient’s report
of a reduction in fatigue indicates that there is a change in the patterning of the energy
field toward a shorter wave, higher frequency and more diverse pattern – promoting
harmony within the interactions between the two energy fields. Light may serve as a
stimulus for change through re-patterning of the human energy field pushing it toward
restoration of the balance and flow of this same energy field.
Summary
Nightingale (1859) and Rogers (1970) recognized the importance of the
environment to the human experience. It has become a field of study for architecture in
building therapeutic environments however there is much more research which needs to
be performed in order to definitively draw conclusions. The environmental elements
placed in a space should enhance the human experience. A variety of interior elements
have been studied for their impact on people. The minimization of noise in the healthcare
environment contributes in decreasing anxiety and facilitating rest (Pattison & Robertson,
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1996). A portrait of nature or a water feature in the lobby of a hospital can enhance a
patient’s sense of comfort and pleasure with their surroundings (Ulrich, 1993; Kaplan &
Kaplan, 1995). The focus for the current proposed research is that of light and its
relationship to a patient’s inpatient experience. As a component of the environmental
energy field, it will be the goal to determine how the light components in the energy field
interact with the patient. Is there an interaction that occurs between patient and
environment energy fields as it relates to light exposure and the patient’s perception of
fatigue and/or mood?
Light’s Effect on the Human Subject
General effects of light. The physiological effect of light is in the form of
invisible wavelengths; it is believed that these light waves may have the ability to modify
the immune response whether traveling through the skin or through the retina.
Wavelengths of light can penetrate the epidermal and dermal layers of the skin and
directly interact with circulating lymphocytes (Roberts, 2000). Lymphocytes are key
players in the body’s immune functions. It is also evident that the lymphocyte activity in
the immune responses is impacted by circadian rhythm. Human circadian rhythm also has
an explicit relationship to light.
Physiological research on phototransduction of light suggests that blood cells with
photoreceptive abilities move through the body to support protein and collagen synthesis
resulting in rapid regeneration of tissue (Campbell & Murphy, 1998). The research by
Campbell and Murphy (1998) included fifteen subjects acting as their own controls.
Subjects were exposed to dim light without their knowledge and during waking as well as
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sleep times. Evidence suggested that endogenous phototransduction occurred with
corresponding changes in melatonin production and core temperature. The connection
between light therapy and tissue healing has been identified through a variety of wound
treatment studies (Barolet & Boucher, 2010; Demidova-Rice, Salomatina, Yaroslavsky,
Herman & Hamblin, 2007; Rennekampff, Busche, Knoblock & Tenenhaus, 2010). It is
logical to posit that light could serve as a stimulus for cellular repair activities. In oriental
medicine, light as a treatment modality is believed to move along the meridians, which
serve as pathways for acupuncture and acupressure (Cocilova, 1999).
Stimulation of the pineal gland and hypothalamus by light is known to produce
serotonin that can be converted to melatonin (Tamminga, 2006). The increase in adrenal
gland secretion of corticosteroids is also associated with light exposure. A systematic
review by Morgan & Rashid (2009) provided supportive information regarding the
impact of light on neutrophil activity. Phototherapy with and without photosensitive
pharmaceuticals has demonstrated a propensity to modulate immune responses.
Autoimmune and skin disorders (e.g. psoriasis) respond positively to light therapy. These
types of physiologic reactions support the theory that light has the ability to enter not
only through the retinal receptors but also through the skin providing a direct line to the
immune system (Roberts, 2000).
The first study to look at the side effects and/or toxicities associated with BLT
was recently published. Botanov & Ilardi (2013) completed a placebo-controlled trial
focusing on the side effects associated with BLT as there is a void in the research on the
therapy’s side effects and tolerability. Using healthy participants, the study had 2 groups.
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The control group received light box exposure emitting 450 lux of red filtered light for 30
minutes compared to an experimental group who received unfiltered white light at 10,000
lux for 30 minutes once daily. The Toronto Side Effect Scale (TSES) was used to
measure the occurrence of adverse treatment events on 17 items. Interestingly enough, of
the 112 red light placebo participants and the 101 BLT participants, the side effects were
statistically significant in the participant experience of eye strain and blurred vision.
Analysis of variance (ANOVA) showed a significant main effect of time on eye strain,
(F(1, 211) = 32.36, p < .001, d = .47), and blurred vision, (F(1, 211) = 7.60, p = .006, d =
.19). Across both groups, the average post-treatment eye strain severity (M= .4, SD = 1.0)
was greater than pre-treatment severity (M = .1, SD = .5) as was the average posttreatment blurred vision
Light's effect on subjective response. The creation of workspaces with sunlight
exposure can increase worker satisfaction (Leather et al., 1998). In an evaluation of the
work environment, researchers examined job satisfaction, well-being and a decreased
intention to quit. The study, conducted in Southern Europe, involved 100 subjects in an
office setting where all workspaces were well illuminated. While no bright light was
directly administered to the workers, sunlight penetration of the work areas was measured
by subjective assessment of the amount of floor area covered by sunlight. The workers’
sunlight penetration assessment for their work area was directly and positively correlated
with increased job satisfaction and general well-being. Intention to quit and anxious
feelings were negatively correlated with sunlight exposure (r = -.32 and -.36,
respectively, p < .001). Positive work attitudes were found to correlate with the size of
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sunlight areas provided in the work place (r = +.25, p < .01) as well as the natural
elements which were available to view via the window exposure (r = +.27, p < .01).
Ulrich’s (1984) findings suggested positive benefits to hospitalized patients given
access to natural light and elements of nature. In a review of 46 inpatient surgical records,
Ulrich (1984) found that the length of stay was different between patients admitted to a
surgical room with a window overlooking a landscaped area versus patients admitted to
rooms with windows overlooking an exterior brick wall. In this early study, Ulrich
demonstrated that patients assigned to the first room type had a significantly shorter
length of stay, used less pain medication while in the hospital and had a decreased
number of complaints. While this study was a retrospective chart review and had a small
sample size with surgical procedure variability in the sample, it was a significant early
attempt to quantify the inpatient’s experience with light and exposure to the outside.
The amount of natural light entering a hospital room has been shown to influence
a patient's recovery from depression (Beauchemin & Hays, 1996). Patients requiring
inpatient treatment for major depressive disorders were admitted to a unit where all
rooms had windows. Researchers categorized patient rooms as either brightly lit or dim
based on the amount of sunlight the rooms received. Of the 174 admissions analyzed,
patients in the brightly lit rooms had an average of 2.6 days shorter length of stay (p =
0.05) than patients admitted to lower light level rooms. This suggested that the amount of
light in the room provided benefits to recovery time and could contribute to significant
cost savings of health care dollars. The researchers were not able to control for all of the
obvious patient differences such as psychiatric diagnoses, age and past psychiatric
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history. An incidental yet significant finding was that male patients experienced shorter
length of stays than female patients regardless of the room illumination. The study was
replicated by Benedetti (et al. 2001) and colleagues five years later with similar findings.
Only one study was found that investigated a relationship between natural and
ambient light exposure and fatigue associated with chemotherapy (Liu, 2005). Fatigue is
a universally recognized side effect of cancer chemotherapy. Researchers recruited
female patients undergoing outpatient chemotherapy for breast cancer. The study did not
provide BLT but attempted to relate levels of fatigue to actual exposure to light. Patients
wore a wrist device which measured light exposure and activity. The light exposure
experienced by the patients was normally below 1000 lux, a level far below the amount
typically used in BLT. Even with these lower levels of light, the researchers found a
correlation between light exposure and the patient’s report of general fatigue levels.
Using the Multidimensional Fatigue Symptom Inventory Short Form (MFSI-SF), there
was an inverse relationship found between fatigue and light levels for all patients. In the
first 2 weeks of each cycle, researchers found higher light exposure correlated with a
greater decline in subscales scores on the MFSI-SF. All subscale scores except for Vigor
are interpreted as the higher the score, the greater the fatigue. But for the Vigor subscale,
a higher score translates to less fatigue. The more light the patient was exposed to during
cycle 4, the higher the score on the Vigor subscale (r=0.28, p=0.045). A negative
correlation was seen in light exposure and the subscale, General (r=-0.30, p=0.031) as
well as in the overall MFSI-SF score (r=-0.30, p=0.033). The findings suggest, but cannot
confirm, a cause and effect relationship between fatigue and decreased light exposure.
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Subscales of the measure individually supported this trend. There is a question of whether
the light is actually decreasing the subject’s perception of fatigue by improving the
patient’s mood or are patients spending less time in moderate to high light exposure
because they are fatigued? Depressive moods, fatigue and loss of energy are frequent
symptoms of patient receiving chemotherapy or radiation therapy for cancer.
The impact of natural or ambient light on the subjective and objective responses
of the individual has not been extensively studied. The research on light used as a therapy
centers on the application of bright light therapy (BLT). The application of this increased
dosing of light exposure has been extensively studied in specific types of depression and
neurologic conditions such as Parkinson’s and Alzheimer’s Diseases. It is fundamental to
the present research to first develop foundational research that light does relate to fatigue
before proceeding to study the use of BLT as a therapy for fatigue in the cancer patient
population. However the research evidence related to BLT will be presented to provide a
comprehensive view of light and how it relates to various states and symptoms.
Bright light therapy. Application of light correlates with bodily increases in
rectal temperature and levels of urinary melatonin, particularly when the color and
intensity of light is manipulated (Morita & Tokura, 1996). Patients were exposed to
varying light color temperatures as measured in Kelvin (K). The Kelvin scale is a
thermodynamic (absolute) temperature scale (New World Encyclopedia, 2010) which
correlates to light color as well as temperature. For reference, 98 degrees Fahrenheit
equals 309.82 Kelvin. Subjects had temperature monitoring and urinary melatonin
measured. The use of a high color temperature light such as 6500 K suppressed normal
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nocturnal temperature fall and suppressed the normal nocturnal production of melatonin
as compared to lights of 3000 K.
The use of BLT in SAD and non-SAD depressed HIV positive patients
demonstrated small alterations in the patients' T cell counts (Rosenthal, Brown, Oren,
Galetto, Schwartz & Malley, 1994). In this cross-over design, subjects were exposed to
45 minutes of either white light or red light. The blood samples taken from the subjects
demonstrated a small but significant increase in CD4 and CD8 cell counts in subjects
who received the white light when compared to counts of patients receiving red light. The
patients with a history of SAD demonstrated improved mood however this was not
observed in the patients with a non-SAD depressive disorder.
The use of BLT is a well-established therapeutic intervention for those individuals
who suffer from SAD (Lam, et al. 2006; Wileman, et al. 2001; Wirz-Justice, et al. 1996).
However, research has revealed evidence that BLT benefits individuals with non-SAD
type depression.
An early study looking at the effects of BLT on normal functioning elderly was
completed by Fukuda and colleagues (1998). Subjects received 30 minutes of BLT at
6000 lux in the morning. Using a visual analog scale (VAS), the seven male subjects
recorded their feelings in the morning and in the evening on seven criteria: alertness,
mood, motivation, tension, fatigue, concentration and appetite. To create a control group,
the same subjects were also instructed to sit without BLT for 30 minutes. All of the VAS
parameters increased in the morning scoring with the BLT conditions and in the evening
all VAS parameters declined (p < 0.05).
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Research on the effects of BLT on healthy individuals (Group 1) as compared to
sub-syndrome SAD individuals (Group 2) demonstrated that both groups could benefit
from BLT (Partonen & Lonnqvist, 2000). This cross over design included four weeks of
BLT (1 hour each day, 5 days per week) at 2500 lux alternated with four weeks of no
therapy over a sixteen-week period. Researchers found benefits for both groups in subject
reports of energy levels, sleep quality, physical activity, and socialization (r ranging from
+.22 to +.18). Both groups reported higher levels of vitality at weeks 4 and 12 however
Group 1 scored a little over 10% better. Both groups reported a significant reduction in
depressive symptoms. Group 2 experienced slightly better improvement of subjective
energy and quality of sleep as compared to Group 1. The significance of these findings
implies that individuals without any evidence of tendencies toward SAD depression
(Group 1) could benefit from BLT.
McEnany and Lee (2005) used BLT in outpatient treatment for depression in
female patients. Subjects used a light visor worn by the treatment group that administered
10,000 lux of light for one hour in the morning. Research variables included depressive
moods, fatigue and energy. With the treatment group of 16 women, the researchers found
significant improvement in depressive moods demonstrating more than a 40% drop in the
treatment group scores. The treatment group also experienced a dramatic increase in the
measure of perceived energy (>40%) while the placebo group experienced a drop.
Improved sleep was also significant in the treatment group with only a minimal change in
the placebo group.
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Light therapy is known to manipulate or modulate the circadian rhythms. This is
the basis for research with SAD. It has also shown to be effective in alleviating delirium
seen in the intensive care patient. Taguchi, Yano, and Kido (2007) studied intensive care
patients who had undergone surgery for esophageal cancer. Post extubation, the patients
were randomized to a control or treatment group. Eight patients were randomized to the
study group and 7 to the control group. The treatment group received 5000 lux for two
hours each morning while the control group received the normal amount of light in an
intensive care patient room measured at 600 to 1000 lux. Only six patients could be
evaluated in the treatment group. Five patients were evaluated in the control group. Sleep
pattern and activities were evaluated as well as delirium. A 30 point confusion scale was
completed by the nursing staff with higher scores indicating more normal functioning.
There were no statistically significant differences between the groups when looking at
activity or autonomic activities. However, there were significant differences in the
delirium scores of the two groups. The control group displayed 24% more delirium than
the study group (p = 0.014). In addition, the study group patients were able to begin
ambulation 2 days earlier than the control group. Hallucinations and auditory
hallucinations disappeared in the study group at the initial day of BLT.
Neikrug and associates (2012) utilized bright light therapy in women undergoing
chemotherapy for breast cancer hypothesizing that women who received BLT would
maintain a healthy sleep-wake cycle while a control group of breast cancer chemotherapy
patients receiving dim red light would demonstrate a greater disruption in this circadian
rhythms. Actigraphy was used to monitor circadian rhythm variables of sleep-wake and

41
activty in both groups. Mesor, the average value around which a variable oscillates, was
used as one of the variables. If sample size is small or the rhythmic process has data
points that are not equidistant, the mesor can produce an unbiased estimator of central
tendency in the analysis of circadian rhythm research (Dictionary of circadian rhythm,
2015). The researchers demonstrated specific variables such as mesor and amplitude had
significantly different changes between the two groups. The control group experienced a
decline in mesor between baseline and cycle 4 treatment week (t=-2.67, p=.009)
suggesting decreased activity of the circadian rhythms. The BLT group demonstrated a
significant increase in mesor at cycle 4 recovery week (t=2.32, p=.02) indicating a more
robust circadian rhythm. Similar changes were seen in the amplitude as well. The BLT
group experienced significant increase in cycle 4 recovery week which would indicate
stronger circadian rhythms (t = 2.31, p = .02) while the dim red light group had a
decrease from baseline in cycle 4 treatment week (t = -2.67, p = .009) which would
indicate decline in activity and/or stability of the circadian rhythm.
Patients undergoing a partial or complete esophagectomy frequently have a
difficult post operative course often involving extended periods of intensive care which
creates opportunities for sleep disruption and delirium. Ono and colleagues (2011)
administered BLT to a study group (n = 10) while a control group (n = 12) received only
natural and ambient light available in the intensive care setting. The study group was
administered BLT for 2 hours in the morning on post op day 2-4. The measure of night
activity was used as a proxy for sleeplessness. The amount of night activity for the
intervention group (21.9 +/- 1.5 hours) was significantly lower than the control group
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(24.1 +/- 3.2 hours) (p< 0.05). The study group demonstrated lower scores on the
NEECHAM confusion scale used to measure delirium, however the analysis failed to
show significance. The researchers postulated that the increased orientation seen in the
study group may have been significant if a larger number of participants could have been
accrued to the study.
Redd and colleagues (2014) performed a randomized study involving light
exposure on 36 cancer survivors. Patients were breast or gynecologic cancer survivors
who were either at least 3.5 years post stem cell transplant (SCT), or up to 3 years post
chemotherapy or chemotherapy/radiation. Patients were randomized to BWL or DRL.
Participants completed the FACIT-Fatigue tool at baseline, during the second week of the
intervention, at the end of the fourth week of intervention and three weeks post
completion. The FACIT-Fatigue required a score of </= 30 for clinically significant
fatigue. Patients used either a light box that delivered bright sun like light at 110,000 to
120,000 lux (BWL, equal to natural sun light) or dim red light (DRL) that emitted < 50
lux. Patients received 30 minutes of light therapy every morning within 30 minutes of
waking and this was continued for 4 weeks. Patients also completed the Brief Symptom
Inventory-Depression score. Results showed a difference in baseline fatigue scores. There
was a change in fatigue scores over time between the two groups with BWL having
significantly less fatigue than DRL (F(1,28) = 7.12, p = 0.0125). Researchers found that
depression was not a predictor of cancer related fatigue. At the end of the intervention all
of the patients assigned to BWL had scores of > 30 on the FACIT-fatigue scale while
55% of DRL patients still showed significant fatigue scores.
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BLT in the Elderly
Depression in the elderly occurs at similar rates as the general population. Elderly
inpatients in the rehabilitative environment for stroke and spinal injury were treated with
BLT (Tsai, Wong, Juang, and Tsai, 2004). The participants were not diagnosed with
SAD. The average length of stay for the control group was 56.4 days and for the
experimental group was 76 days. Participants were identified as having mild to moderate
depressive moods but were not previously diagnosed or treated for depression. In
addition, the subjects did not suffer from any significant cognitive dysfunction. The
experimental group received 50 minutes of BLT (5000 lux) for 5 days and no treatment
was provided to the control group. Using the Geriatric Depression Scale, scores of less
than 10 are considered normal, 10 to 19 considered mild depression and scores greater
than 19 indicate severe depression. Significant decreases in depressive moods were noted
in the experimental group scoring 18 on the pre-test and 13.2 on the post test. The
underlying co-morbidities between the groups were not a factor. The control group only
experienced a 0.1 decrease between pre-test and post test scores. While only one study,
these findings suggest benefit in the use of light therapy on rehabilitative patients who
experience longer lengths of inpatient stays.
Numerous studies have investigated the effects of BLT in the elderly with
cognitive dysfunction such as those with dementia (Hickman et al. 2007) and
Alzheimer’s disease (Ancoli-Israel et al. 2003). Many researchers have used BLT to treat
depression while others have examined its impact on the activity-rest cycles, particularly
in the institutionalized elderly. These studies may have implications for the BMT patient
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as disruption of the circadian rhythm can occur in the BMT patient due to hospitalization
or side effects from the treatment.
The assertion that BLT could benefit the cognitive functioning of dementia and
Alzheimer’s disease type dementia was supported in 2001 (Graf, et al. 2001). The effect
of BLT (3000 lux) and dim light therapy (100 lux) on Mini-Mental State Examination
(MMSE) scores was the focus in a small study involving institutionalized adults with
dementia. The use of BLT was associated with a significant increase in subject MMSE
scores. Every patient in the BLT group that was able to complete the MMSE pre and post
BLT had an increase in score from 15.2 to 18.1 (p = .0012); a similar change was not
found in the control group receiving dim light therapy. In 9 of 10 patients in the dim light
group, only 3 patients had an increase in score. The remaining 6 either had similar or
decreased scores. A component of the research was also the measurement of body
temperature investigating its relationship with regulation of circadian rhythm. Body
temperature changes seen were short lived which could possibly mean the effects of BLT
might be short lived as well. Because a repeat measure of the MMSE was not performed
posttest on day 10, this could not be validated. This research involved light
administration between 5:00 and 7:00 pm for 10 days. The timing of the light
administration was different from a majority of the reviewed research; other studies were
careful to avoid evening hours for light administration. The researchers did not indicate
their rationale for the timing of light administration.
A research team headed by Ancoli-Israel (et al. 2003) hypothesized that BLT
could reduce evening agitation in Alzheimer’s patients by manipulating the circadian
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rhythm. The team observed that, patients who were awake during the night displayed
agitation consistently throughout day and night without any observable period where
there was no agitation. If the patient spent more time awake during the day, there were
periods during the night and day that patients exhibited less agitation. The light levels
institutionalized patients are exposed to are typically below 1000 lux. Ninety-two patients
were enrolled in this study. Agitation was measured with two tools; one tool involved the
caregiver rating the level of agitation over a prior 2-week period. A second tool was a
behavioral rating scale completed by trained individuals with high level of inter-rater
reliability evidence. Patients were randomly placed in one of three treatment groups to
receive morning BLT, dim red light (placebo) and evening BLT. The physical agitation
for the morning BLT was delayed during the treatment period when compared to baseline
by 1.63 hours (p = 0.034). Of staff appraisals of patients, there were significant changes
across all treatment groups. Staff rated declines in scores for physical agitation (10.4 to
9.6, p = 0.007), verbal agitation (11.3 to 10.0, p = 0.001) and total agitation (29.7 to 26.9,
p = 0.0004) in all groups.
The research continues to be unclear on the exact prescription for BLT in the
Alzheimer’s disease patients. There may be specific criteria that researchers need to
evaluate to further define where the therapy can be of greatest benefit. Schindler and
colleagues (2002) published a report on five patients with Alzheimer’s disease with and
without delusions. Of the five patients, three were experiencing delusions. In these three
patients, BLT was administered at 2500 lux for two hours daily. This treatment resulted
in a slight improvement. One patient did not have delusions before, during or after the
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BLT however one of the subjects experienced an increase in hallucinations and delusions.
The researchers found that the level of disorientation increased with the BLT and the
BLT had to be discontinued. The ability to make general assumptions on BLT therapy
enhancing the Alzheimer’s disease patient’s orientation or agitation remains elusive. This
research group emphasized that in the Alzheimer’s disease patient population, BLT
should not be continued in the face of any increase in agitation, delusions or
hallucinations.
In the absence of depression, BLT was employed to successfully improve sleep in
the institutionalized elderly (Fetveit et al. 2003). A small study (11 participants) with
institutionalized elderly of varying degrees of dementia used BLT at levels of 6000-8000
lux for two hours in the morning. Researchers focused on sleep-wake disturbances such
as number of awakenings, length of each awakening, waking after sleep onset and early
morning awakening utilizing actigraphy monitors. Sleep efficiency improved in all
patients by 13%; this translated into subjects falling asleep faster and experiencing less
awakenings. Total time in bed decreased by about one-half hour while rising time
remained unchanged. The patients experienced a decrease in sleep onset of 1 hour
without an observed change in rising time. The researchers found a decrease in time spent
on nocturnal waking by as much as 2 hours from pre-treatment to post treatment. As the
BLT became more intense, greater improvement was found in the sleep-rest experience
of the patient. The study participants had some dementia however the researchers did not
provide a discussion of the level or severity of dementia.
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Research on cognitively impaired institutionalized adults is challenging, as
responses may need to be assessed by proxy. Hickman and colleagues utilized ambient
bright light therapy with patients classified with varying degrees of dementia (Hickman,
et al2007). The bright light levels were not as high as typically used (2533-2638 lux).
Two study sites were used in different regions of the country. There were four light level
interventions administered to the participants with each intervention lasting 3 weeks in
length. The four interventions were: (A) 4 hours bright light in AM, (B) 4 hours bright
light in PM, (C) all day bright light, and (D) standard lighting. Participants had multiple
interventions over the course of the study. During each intervention, depressive
symptoms would be measured. The researchers found mixed results with some subjects
experiencing a negative response to the light. In general, females in the study experienced
greater improvement in depressive symptoms with morning light versus standard light
(p=.01) while their male counterparts experienced more depressive symptoms under
morning bright light than with standard lighting (p=.007). Using the Cornell Scale for
Depression in Dementia, researchers did not find many statistically significant
differences between gender other than higher overall depressive symptoms in men than
females regardless of study site. The use of bright ambient lighting challenged the
researchers to create consistent light levels throughout the institution at a cost that would
be prohibitive for most institutions. This was an extremely complex and probably very
expensive study and while the findings were not impressive, it did demonstrate
interesting gender differences with regard to the effect of light and generated questions
about gender depressive responses to lighting conditions.
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Dowling and colleagues (2007) studied the effects of light on neuropsychiatric
behaviors in patients with Alzheimer’s disease. Subjects were randomized to a control
group or to one of two study groups. The control group received no BLT but experienced
normal room light within the range of 150 to 200 lux. Within the study groups, each
subject received either one hour of morning BLT or afternoon BLT. Researchers
evaluated the subjects for changes in the presence, frequency, severity and disruptiveness
of neuropsychiatric behaviors in nursing home patients. A larger score was interpreted as
subjects having greater severity or frequency of problematic behavior. Statistically
significant findings were seen in the behavior categories of agitation/aggression,
depression/dysphoria, and aberrant motor behavior. Patients receiving BLT had lower
severity and frequency scores, however the actual scoring changes were minimal. The
researchers attributed the scoring as innate to the tool stating that the significance found
did not translate in clinically meaningful results. Of note, this study relied heavily on staff
interpretation of the subject’s behavior which could interject greater variability in
scoring. However a second study by Dowling, et al. (2008) investigated the sleep
behaviors of a similar population melding light therapy with the addition of melatonin.
Within the myriad of Alzheimer’s disease, there is great disruption noted with the
circadian regulation and one would expect some subject reaction to BLT. The inclusion
of oral melatonin at a dose of 5mg to the trial provided a different approach than typically
seen in the literature. Research is suggestive that melatonin is low in Alzheimer’s
patients. The control group received no interventions while the two experimental groups
received BLT with melatonin (LM) versus placebo (LP). Actigraph wrist monitors were
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used to monitor activity on all patients. The BLT was administered via light box with
each subject in the experimental groups receiving on average 6204 lux. While no
significant changes were seen in the night sleep time, there was a significant reduction in
daytime sleep by 66 minutes. Subjects in the LM group demonstrated increased daytime
activities and improvement of day/night sleep ratio. The LP group and control group
experienced an increase in daytime sleep time (p < .001). The differences in responses
were impressive with only one hour of BLT daily for this 10-week trial.
Research findings have suggested that the decline in melatonin production may be
an important factor in the neurodegeneration seen with aging (Jenwitheesuk, Nopparat,
Mukda, Wonchitrat, & Govitrapong, 2014). If true, then light therapy to manipulate
natural melatonin production may be of use. Researchers proposed that bright light
therapy (BLT) could have a positive effect on the symptoms of Parkinson's disease (Paus
et al.2007). Subject selection provided for a control and placebo group with similar
characteristics in stage of disease, physiological functioning and mental ability. Subjects
received light box exposure for thirty minutes just after rising; the study group (N =18)
received 7500 lux daily through light box and the placebo group (N =18) received a much
smaller BLT dose. No significant changes were found in the placebo group. In the study
group, researchers found a statistically significant increase in mood with a 25% decline in
scores on the Beck Depression Inventory. Since none of the subjects had a diagnosis of
depression, the change in the study group was attributed to the BLT. The United
Parkinson's Disease Scale (UPDRS) was used to measure mentation, mood and behavior.
The study group revealed an over 30% improvement in scores on the UPDRS. The BLT
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produced a small improvement in the incidence of tremors and ADL function with
slightly over 10% improved scores (p < .05 and p < .01 respectively). There were no
significant findings in scores for rigidity and bradykinesis.
While the relationship between neuropsychiatric conditions in the elderly and
BLT is far from conclusive, current research has provided the scientific community
enough interest for further investigation. BLT is a low risk, non-invasive intervention
which may provide higher quality of light and/or improved functioning for this particular
patient population.
Researchers have investigated illumination levels experienced by nursing home
patients (Schochat, Martin, Marler & Ancoli-Israel, 2000). Light levels were measured
for a small group of 66 patients with dementia. The mean daytime light exposure was
only 485 lux with almost 30 % of the subjects never being exposed to light over 1000 lux.
Interior light levels typically are in the 400-500 lux range. In this research, light levels
were negatively correlated with the number of awakenings at night (rS = -0.35, p =
0.004); this finding was not impacted by the patient’s level of dementia. Using Spearman
rank correlation, time spent at lux greater than 1000 showed a tendency toward predicting
fewer awakenings during the night (rS = -.21, p = 0.089) but failed to reach statistical
significance. In this patient population, severe dementia has typically been a predictor for
increased sleep time and decreased wake time during the day. However in this study, the
use of BLT was able to minimize the impact of the condition. Interestingly, the overall
time spent in high illumination levels may be more important than short sessions at
higher lux. There are research efforts ongoing to integrate the use of BLT in the
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environment of the elderly to enhance cognitive function and minimize delirium (Chong,
Chang, Kang, Han, Ding & Tan, 2011). BLT was built into a 5 bed unit specifically
designed for geriatric patients with delirium. BLT of 2000-3000 lux was administered via
ceiling lights from 6-10pm daily. The sample size of 228 patients was recruited from this
unit over a 2 year time period. Functional status was measured via modified Barthel
Index (MBI) with patients with hyperactive or mixed delirium subtypes showing
improvement in scores (p < 0.05). The Delirium Rating Score at the sleep wake
disturbance subscore showed significant improvements in all three delirium subtypes.
Sleep improvements were primarily seen in hyperactive delirium patients: sleep time
went from 6.4 hours to 7.7 hours (p < 0.05) with a decreased mean number of sleep bouts
and awakening.
Based on the provided research, suffice to say there is a relationship between BLT
and the inner workings of the human ‘clock’. While the physiological or psychological
reaction appears varied dependent on the patient population being investigated, there are
human responses that occur related to the BLT. It is also important to note that light has a
definitive relationship with the circadian rhythm. This relationship may be pivotal in
understanding how light may produce changes in fatigue, as both the sleep-wake activity
and fatigue are activities controlled by the hypothalamus. Low light levels of < 400 lux
are similar to the light levels experienced by the BMT patients whether in hospital or
home. There can be a suggestion of light’s relationship with perception of fatigue
however this has not been well explored in this cancer patient population.
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Fatigue
Fatigue in general can be defined as a subjective experience encompassing
weariness, tiredness or lack of energy (Dimeo, 2001). Fatigue occurs in all of us in the
absence of disease but because of its pervasiveness in the cancer population, the term
cancer related fatigue (CRF) has emerged. It is the most common symptom experienced
by cancer patients (Cella, Peterman, Passik, Jacobsen, & Breitbart, 1998). While a
universal complaint during treatment (Berger, 1998; Byar, Berger, Bakken & Cetak,
2006), it also remains an issue for many patients in the post treatment period at varied
levels of intensity and duration. Fatigue has great impact on the patient’s ability to
tolerate any prescribed cancer treatment and can have a deleterious effect on the patient’s
ability to stay on course with treatments (Dodd, Miaskowki & Paul, 2001).
Cancer related fatigue. Cancer related fatigue can be defined as "a persistent
subjective sense of tiredness related to cancer treatment that interferes with usual
functioning" (National Comprehensive Cancer Network, 2011). It has been studied in a
variety of cancer types, in progressive, metastatic disease as well as in adjuvant
chemotherapy patients with no signs of disease and in patient populations prior to, during
and after treatment. The difference between cancer related fatigue and fatigue the general
population experiences is that rest does not alleviate the cancer related fatigue and it is
not the result of physical activity (Yavuzsen, Davis, Ranganthan, et al. 2009). It does not
appear that the fatigue experienced by patients during cancer treatment can be directly
related to nutritional status (Beach, Siebeneck, Buderer & Ferner, 2006).
Researchers continue to investigate the components of cancer related fatigue because
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of its prevalence in all cancer patient groups; depending on the study, its prevalence is
stated anywhere from 25% to 99% in patients with cancer (Servaes, Verhagen, &
Bleijenberg, 2002). The pathophysiologic etiology of it is still in question.
It is unclear whether cancer fatigue is a muscular phenomenon or whether it is
more centrally generated through neuromuscular activities. Researchers hypothesized that
fatigue during prolonged motor tasks in cancer patients would be more centrally located
than in healthy controls (Yavuzsen et al, 2009). Subjects completed the Brief Fatigue
Index to measure the patient's perception of the fatigue experience. Subjects (n= 29) had
a variety of advanced cancers and were compared to 16 healthy controls. The research
team measured maximum elbow flexion force using instrumentation. The instrument
provided numeric readings of the patient’s strength in sustaining elbow flexion against a
constant pressure Patients with cancer fatigue had significantly less ability in elbow
flexion force than healthy controls (186 + 69 vs. 257 + 77, p < 0.01). This finding
suggested that patient with CRF had weaker muscles to sustain the elbow flexion than
health controls. But the healthy controls experienced greater muscular fatigue after the
sustained elbow flexion contractions than cancer fatigue patients (66% versus 46%, p <
0.05). This is suggestive of the hypothesis that cancer fatigue is not due to muscular
fatigue.
While this research can provide differences in muscle potential between the
cancer related fatigue patient and the healthy subject, the etiology of this
multidimensional condition is far from understood. The literature is just beginning to
delve deeper into a potential relationship between hypothalamic-pituitary-adrenal activity
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(HPA) and cancer related fatigue. This relationship is of great interest to the present
research for the mere fact that light also has a relationship with hypothalamic and
pituitary activity.
Cancer related fatigue and inflammation. There is speculation on the role of
the inflammatory process in the development of cancer related fatigue (CRF). In the
pretreatment patient, CRF may develop due to a pro-inflammatory response to the disease
process. During treatment, it is hypothesized the biochemical changes causing CRF
development are generated by the treatment regimen (Prue et al 2010; Mills et al. 2005).
It is difficult to conceive that this inflammatory response could also serve as a rationale
for long term CRF in patients who have completed therapy months or years earlier. Work
has also been performed on these inflammatory markers which may explain CRF's
persistence or latent development (Collado-Hidalgo, Bower, Ganz, Cole & Irwin, 2006;
Kruse & Strouse, 2015; Wang, Shi, Williams, Shah, Mendoza et al. 2015).
As early as 2001, research focused on identifying the relationship between
chronic fatigue and the hypothalamus-pituitary-adrenal (HPA) functions (Cleare, Blair,
Chambers, & Wessely, 2001). While the current proposed research will look for any
connection between light and fatigue, it does not intend to provide further identification
of biochemical changes due to this interaction. Suffice to say that the HPA connection
and inflammation with fatigue is important to the present hypothesis, that light correlates
with fatigue based on the same area of physiologic involvement.
Alexander, Minton, Andrews & Stone (2009) utilized defined criteria for
establishing the presence of CRF in 208 breast cancer survivors who were out of
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treatment between 9-11 months. They found that 60 (30%) women met the criteria for the
diagnosis of CRF. A battery of tools was administered to the subjects measuring fatigue,
quality of life, depression and work/social adjustment. In addition the researchers took
blood specimens for hematologic and biochemical analysis and collected a 24 hour urine
specimen for urinary cortisol. There were significant differences in the non-CRF and
CRF groups on the Total BFS for fatigue (21.47 vs 54.07, p<0.001), and on the Total
HADS score for depression (2.55 vs 5.58, (p<0.001); data showed greater levels of
fatigue and depression in CRF subjects. There were no significant differences in urinary
cortisol level between groups but there were some differences in the WBC counts and
chemistry blood levels. Finding differences in the urinary cortisols could have
contributed to the pro-inflammatory theory for CRF, but the study did not support the
researcher's hypothesis.
Bower and colleagues (2011) examined fatigue and gene expression in support of
the hypothesis that pro-inflammatory cytokines play a role in cancer related fatigue. This
study was performed with breast cancer survivors who had persistent fatigue (n=11) and
who did not have persistent fatigue (n=10). The researchers proposed that the fatigue
group would have reduced activity in the glucocorticoid receptor which does not promote
inhibition of NF-kB and other pro-inflammatory signaling pathways. The researchers
found 437 transcript genes with greater than 30% difference in expression of leukocytes
from the fatigue versus the non-fatigued subjects. The fatigued group had increased
numbers of genes encoded with pro-inflammatory cytokines (p< 0.001) associated with
increased activity of cytokines involved in immune and inflammatory response. A
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reduced expression with response elements for glucocorticoids in the fatigue group was
present (p<0.05). This was a very small study however it was able to show cellular
differences between the fatigue breast cancer survivor and the non-fatigued breast cancer
survivor.
CRF research has been studied predominantly in the breast cancer patient
population. Studies have captured fatigue intensity during intercycle monitoring of
adjuvant therapy (de Jong, Kester, Schouten, Abu-Saad & Courtens, 2006).
Andrykowsky, Donovan, Laronga & Jacobsen (2010) utilized criteria for establishing the
presence of CRF and assessing breast cancer (BC) patients at baseline, 6 months and 42
months post treatment. Comparisons were made between breast cancer survivors (n=304)
and an equal number of healthy controls. Baseline measurement of fatigue in the BC
group was comparable to prevalence at the 6-month mark post treatment (9.9% versus
9.2%). Of interest was that as high as 33% of the patients met the CRF criteria at all
assessed time points. Finally, the off treatment CRF measure was 13.1 % in the BC
group. This suggested that patients could experience delayed onset of CRF even in the
absence of active treatment.
Fatigue in breast cancer has been widely studied more so than fatigue associated
with any other cancer type. While breast cancer is not frequently treated with PBSCT,
autologous transplant has been used as a treatment option for the patient population.
Depending on the study, as many as 60% of breast cancer patients can suffer from
moderate to high levels of fatigue for as long as one year after the transplant (Winer et.al.
1999). While allogeneic patients statistically have a more difficult recovery, both
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autologous and allogeneic patients are plagued with fatigue as well as insomnia and
negative mood (Watson et. al. 2004). In general, treatment related symptoms associated
with transplant do not vary based on the primary cancer site or cell type.
Hoffman, Given, von Eye, Gift & Given (2007) examined the relationships
between common symptoms experienced by newly diagnosed lung cancer patients who
were within 56 days post chemotherapy. Not surprising, the researchers found that 97%
of the patients stated that fatigue was the most significant symptom (p = 0.05) with pain
coming in as second most significant at 68%.
CRF has been studied in patients with gynecological cancer, focusing on the
fatigue during treatment as well as after the treatment has been completed (Prue, Allen,
Gracey, Rankin, & Cramp, 2010). In a randomized trial, Prue and associates (2010)
investigated the differences in severe fatigue between gynecological cancer patients
(n=65) and healthy controls (n = 60). A key goal of the study was to determine any
predictors for severe fatigue. Through the use of several tools with subscales for fatigue
and symptom checklists, the findings suggested that symptoms may stem from both the
disease as well as a post treatment changes. The fatigue experienced by the cancer group
was significantly higher than healthy controls at all time points: before treatment, during
treatment and after treatment (p < 0.001). At monthly time points, the fatigue experienced
by the cancer group was ten times higher than the healthy group. Data collection
continued monthly for 11 months. The psychological distress level was the only
independent predictor of CRF (p < 0.001) during treatment and one of two predictors of
fatigue after treatment (p < 0.001).
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Fatigue in the BMT patient. For the patient undergoing cancer treatment via
bone marrow or stem cell transplant, fatigue has often been studied as a component of
quality of life. There are limited studies which focus on fatigue as a primary variable.
However, the studies that are present suggest that it is a symptom prior to treatment, a
symptom during treatment and can be a chronic symptom for years post- transplant. In
addition, the majority of studies investigating the transplant experience look at the long
term symptoms that effect the patient's quality of life rather than the time period pretransplant to the first 100 days post transplant (Akaho et al. 2003; Andrykowski et al.
2005; Hayden et al. 2004).
Winer and colleagues (1999) found 60% of patients complained of moderate
fatigue one year after receiving BMT for breast cancer. Those patients with less fatigue
were found to have a significantly higher scores on the quality of life tool (r = -0.61, p =
0.001). Watson (et.al. 2004) found similar issues with fatigue when comparing quality of
life issues between allogeneic and autologous transplants. In the total sample, the
researchers found 79% of patients complaining of fatigue. A difference between the
allogeneic and autologous fatigue complaints was not significant in patient percentages
(87% versus 81% respectively). In another study, for patients receiving allogeneic
hematopoietic stem cell transplant, the number one most prevalent and significant
complaint at baseline was that of fatigue (Bevans et al. 2008). For these patients' first 100
days post-transplant, fatigue remained the first or second significant symptom in
prevalence and distress at baseline, day 0 (at the day of PBSC infusion), day 30 and day
100.
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Coleman and colleagues (2002) focused on patients undergoing very aggressive
treatment for multiple myeloma utilizing stem cell transplant as one of the modalities.
This chemotherapy regimen included induction with a variety of neoplastic medications,
consolidation chemotherapy and tandem stem cell transplant. The patients were also on
maintenance dosing of alpha interferon. The overall purpose was to control symptoms for
patients and compare patients who successfully received outpatient transplant care versus
patients who had unplanned admissions where they received the bulk of the therapy.
Fatigue was measured by the patient stating the percent of usual energy they felt on a
defined day prior to transplant, day of transplant and post transplant. All of the patients
experienced an increase in fatigue but the patients who were successfully treated and
managed as outpatients (n = 73) had less severity and intensity of fatigue than patients
with unplanned hospitalization (80% versus 68%, p = 0.017). One could postulate
multiple reasons, such as more fit patients would be the candidates to receive primarily
outpatient treatments. Researchers could not clearly explain the underlying rationale for
the differences.
Danaher-Hacker and colleagues (2006) completed a descriptive, exploratory study
examining levels of fatigue in the immediate pre- and post-transplant periods, in addition
to evaluating other variables. The goal was to identify any changes in fatigue, physical
activity and sleep during the five days prior to and the five days after the infusion of stem
cells post chemotherapy. Using a convenience sample (n = 20), the researchers utilized an
Actiwatch in addition to a quality of life tool with three multi-item symptom scales for
fatigue, pain, nausea and vomiting and single item questions about other physical side
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effects such as sleep disturbances, appetite loss, dyspnea and gastrointestinal symptoms.
This study mixed autologous and allogeneic transplant patients; this is an important
nuance since the recovery can be vastly different between these two groups. A 10-point
scale was used to subjectively measure the participant's perception of fatigue. Mild
fatigue was reported prior to transplant by 75% of participants on day 1, by 83% of
participants on day 2 and by 88% of participants on day 3. The researchers found a
significant increase in fatigue levels in the immediate post-transplant period. The first day
after transplant, 90% of patients reported moderate to severe fatigue. On the second day,
77% of participants reported moderate to severe fatigue and on the third day, 80% of
participants reported moderate to severe fatigue. With successive days, there was a
dramatic increase in the percentage of participants complaining of moderate to severe
fatigue (90% of patients by day 5). At time one measurement, the mean fatigue score was
29.63 (pre-transplant) compared to mean fatigue score of 71.11 at time two (post
transplant). Researchers also found that participants experienced a 58% decline in
physical activity from day 0 to day 7. An obvious assumption would be that those two
findings are directly related however the researchers did not provide any correlation.
Bevan’s et al. (2008) research also focused on those early time periods with
allogeneic transplant. Four data collection time points were identified including pretransplant, day 0 (cell infusion), day 30 and day 100. Seventy-six transplant patients
participated. Using a symptom distress scale, they found that 90% of the participants
(n=60) rated fatigue as one of the most distressing symptoms and at day 100, 81% of the
participants continued to rate it as highly distressing. Fatigue was the only recurring
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distressing symptom in the latter three data collection times. With this research, the
recovery from fatigue appears extremely slow in the post transplant experience so finding
adjuvant interventions to minimize the magnitude and duration of the fatigue would be of
great benefit in helping these patients return to a pre-transplant psychological and
physiological status.
Fatigue is a universal complaint for the BMT patient during the conditioning
regimen, the stem cell infusion, and can be a prolonged complaint in the long term posttransplant period. Fatigue is recognized for its subjective nature and significantly
increases as physical activity decreases following the high dose chemotherapy and
radiation (Danaher-Hacker, et al. 2006). While fatigue has been studied in the BMT
population, studies differ in assessing its immediacy of onset post stem cell infusion.
Multiple longitudinal studies have identified the chronicity of the symptom for years in
some patients (Prue et al. 2010; Mills et al. 2005). There continue to be further
opportunities to compare over time the type of fatigue experienced by these patients.
There have been suggestions that cancer related fatigue may have a relationship
with the hypothalamus and the pituitary in addition to modulating the production and
transport of a variety of white blood cells (Prue et al. 2010; Mills et al. 2005) While the
immune stimulating properties of light have not been validated, the connection between
how light interacts within the body and its connection to the hypothalamus and pituitary
have been defined (Leproult et al. 2001). Baseline research first must make a connection
between how the duration and intensity of light exposure may correlate with the patient’s
report of fatigue. Only one study was found that investigated any connection. Liu’s
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(2006) study with patients receiving adjuvant chemotherapy for breast cancer found a
relationship between light exposure and reported fatigue.
Sleep disturbance is considered a common complaint of the cancer patient and it
could be projected that it would increase during a patient’s hospitalization. In addition,
there is a feasible relationship between sleep disturbances and the occurrence of fatigue.
Disruption of the sleep-wake cycle can contribute to the fatigue experienced by the
cancer patient and sleep disruption occurs in the patient undergoing BMT (Rischer,
Scherwath, Zander, Koch & Schulz-Kindermann, 2009). In this 2009 study, sleep
assessments were performed prior to hospitalization, during the inpatient stay and up to 3
months post-transplant. Fifty transplant patients consented to participate however only 32
patients completed all assessments. Sleep assessments included the completion of the
Pittsburgh Sleep Quality Index (PSQI) (Buysse et al. 1989). At initial assessment, 32% of
the 50 patients suffered sleeping difficulties. At the post-transplant assessment, 77.3% of
the 32 patients reported an increase in sleep difficulties. For those patients that completed
all assessments, a significant increase in sleep disturbances was seen between preadmission and at 100 days post-transplant (p< 0.001).
Mood Disturbance
Depression, anxiety and distress are frequently present in the patient receiving a
PBSCT. Similar to fatigue, mood disturbance can occur prior to the transplant and can
persist long after the completion of the therapy. While some studies have attempted to
connect survival with the patient's level of pre-transplant depression, this has not been
conclusively determined to be the case (Grulke, Larbig, Kachele &Bailer, 2008). A study
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performed by Jenks Ketterman & Altmaier (2008) with 86 BMT patients found that 29%
of their patients were experiencing depressive symptoms pre-transplant and 27 % met
criteria for clinical depression 1 year post transplant. The researchers utilized the CES-D
(depression subscale) to measure levels of depression with a higher score indicating
higher levels of depression. Scoring range on the CES-D is 0-60 with a score of >/= 16
considered a clinical level of depression. Their investigation demonstrated that pre-BMT
depression was a predictor for depression 1 year post BMT. Similar to gender differences
seen in fatigue studies, females scored higher for depression on the CES-D than males
than males (11.80 versus 16.69 respectively, p=.025).
While many illnesses are associated with mood disturbances, the public’s
association with cancer is one of fear and sadness. Wang and associates (2007)
investigated differences in mood and sleep comparing two patient groups with known
pain issues. Chronic daily headache (CDH) patients (n=47) and chronic cancer patients
(CCP) (n=47) were surveyed using a variety of measurement instruments. Participants
with cancer had varying cell types with the largest number coming from patients with
lung cancer (n=14). The Profile of Mood States tool (Shacham, 1983) was used as well as
the Brief Pain Inventory (Wang, Mendosa, Gao & Cleeland, 1996) and the PSQI (Bussye
et al., 1989). The CCP patient group had significantly more days per month where pain
was present (28.13 days versus 24.45 days, p=0.03). Scoring for the BPI subscales was 0
to 10 with higher numbers equating to maximum negative impact to the patient. Subscale
scores on the BPI demonstrated that CCP patients versus CDH patients perceived more
disruption in performance of general activities (6.53 vs 5.21, p=0.03), walking (6.02 vs
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4.00, p=0.001) and working (7.11 vs 4.66, p<0.001) respectively, due to pain. The only
significant difference between the two patient groups on the POMS was on the Vigor
subscale, with CCP patients perceiving less energy than CDH patients (p < 0.001). For
the POMS-SF Fatigue subscale, there was a trend toward fatigue being a greater issue for
the CCP versus CDH group however it did not reach the required level of significance.
Historically, the bulk of research examining the PBSCT experience has been
through investigation of quality of life. But within those studies, fatigue and mood
disturbances have been identified as variables which dramatically impact the patient's
experience. Researchers still are in search of a uniform and consistent relationship
between mood disturbances and fatigue in this patient population. Molassiotis (1999)
examined the symptoms that hindered the patient during this treatment with 91 BMT
survivors. Two groups were defined: survivors six months post transplant and survivors
receiving maintenance therapy. Using three tools to measure symptoms, the researcher
found that fatigue was highly correlated with anxiety (r = 0.52), depression (r = 0.59) and
psychological symptom distress (r = 0.58) all at p < 0.001. This established mood
disturbance measures as appropriate for the present study along with measures of fatigue.
Again, the use of light has shown success in modulating mood disturbances in specific
patient populations (Ancoli et al. 2003; Hickman et al. 2007; Paus et al. 2007).
Sasaki and colleagues (2000) investigated patients with leukemia (n = 39),
receiving allogeneic transplants during their period of isolation. Sixteen patients (41%)
scored higher on mental disorder criteria with predominant groups being female (p =
0.033) and patients receiving unrelated donor cells (p = 0.026). The research team
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suggested that the period of isolation was instrumental in increasing the scores on mental
disorder criteria. Trask's (et.al. 2002) study demonstrated that as high as 50% of the
patients self reported emotional distress and anxiety (p < 0.05) with 20% of patients
identifying depression as an issue. The 50 patients who participated were all candidates
for allogeneic transplant so the data reflect the patients' emotional status prior to any
conditioning regimen or PBSCT.
The issues of depression or mood disturbance can present throughout the
continuum of care for bone marrow transplant patients. Prieto and colleagues (2002)
investigated the frequency of mood disturbances prior to and during hospitalization for
PBSCT, correlating the presence of mood disturbance with the length of stay for
allogeneic (n = 91) and autologous transplants (n = 129). Participants were interviewed
prior to hospitalization and weekly until discharge or death. Multiple tools were used to
assess psychological adjustment disturbance, including the Hospital Anxiety and
Depression Scale (HADS) (Zigmond & Snaith, 1983). The researchers found no
significant difference between prevalence rates for mood, anxiety or psychological
adjustment disorder between the two groups; 38.8% of autologous patients and 47.3%
allogeneic patients experienced one of these conditions (p = .26). There was, however, an
8% increase in length of stay if the patient had a mood, anxiety or adjustment disorder (p
= .022). Studies which focus on the psychological distress within the first month post
transplant were found with less frequency than those focusing on the long term
psychological wellbeing of this patient group.
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Akaho and colleagues (2003) investigated psychological distress in the post
transplant period in patients diagnosed with leukemia undergoing allogeneic bone
marrow transplant. Of the 72 patients, there was a mix of those patients in their first
remission, the first chronic phase, and later stages of the disease. The Profile of Mood
States (POMS-SF) (Shacham, 1983) was completed by all patients one week prior to the
start of the isolation period. Patients were interviewed at 2-3 weeks into the isolation
period. The researchers abstracted anxiety, depression, anger, fatigue, and confusion data
to combine these into one data grouping. Overall survival and disease free survival was
significantly correlated with gender with female patients being three times as likely to
survive when compared to the male participants (r=0.4-0.8, p=0.05).
There is a definitive need to have more research with a primary focus of mood
disturbances in this patient population. It is most frequently addressed as a component of
quality of life in the PBSCT patient. While the team lead by Schulz-Kindermann (et al.
2007) was investigating the relationship between quality of life and cognitive functioning
in the transplant patient, they found no difference in the emotional or cognitive
functioning prior to transplant and at day 100 post transplant (p = 0.159 and 0.804
respectively). As in many of the transplant studies, the sample size was small for patients
who completed all study requirements (n = 19). The most distressing issue for the
participants of this study was impaired physical functioning, not psychological distress.
Another study performed the same year (Rusiewicz, DuHamel, Burkhalter, Ostroff,
Winkel, et al. 2007) did focus on psychological distress of the PBSCT patient one year or
longer post transplant. The Brief Symptom Inventory (BSI) (Derogatis, 1993) was used,
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providing a global measure of psychological distress. Two of the nine BSI subscales
directly relate to depression and anxiety. In the sample of 236 PBSCT patients, the
researchers found that 23.7% (p < 0.05) of participants suffered from significant
depressions and 22.5% (p < 0.05) from anxiety. Interestingly there were no significant
differences in amount of psychological distress based on length of time post transplant.
The researchers found that 43% of the participants reported clinically significant global
psychological distress. The subscale Obsessive-Compulsive (trouble remembering, mind
going blank) affected the highest number of participants (36.4%) and Somatization (pain,
nausea, weakness) affected 31.4% of participants. While there has been no study to
document the relationship, the authors of this study did discuss a hypothesis for future
consideration. The existence of psychological distress could lead to a heightened selfreport of cognitive symptoms.
Similar to the fatigue experience in PBSCT, mood disturbances can linger long
after the transplant has been successfully completed. Depression was the focus of
research for DeMarinis and colleagues (2009) involving patients 1 year post PBSCT.
They investigated depression in 23 patients within that time frame and found explicit
gender differences in the presence and treatment of depression. Women in the study had a
significantly higher rate of depression (p=0.007) and were more likely to be receiving
antidepressive therapy (p=0.02) at least 1 year post transplant.
Researchers seek methods to remedy the mood disturbances felt by this patient
population. A unique but logical approach, using partner support to combat the distress,
was the focus for Rini and colleagues’ (2011) study. Like many of the available studies,
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Rini focused on the 1- to 3-year post transplant period to investigate partner support as a
predictor of stress in the patient. The study was also performed to see if the quantity of
partner support or the effectiveness of the partner support would have the greatest impact
on the patient. Participants (n = 230) completed tools to define the quantity of partner
support and partner social support effectiveness. There was a negative association
between partner support quantity and distress (r = -.09) however the correlation did not
reach significance (p = .09). Partner social support effectiveness showed a statistically
significant negative significant correlation with distress (r = -.49, p < .001). Participants
who received more effective partner support reported significantly less distress than those
who received less effective partner support. There were interesting predictors of posttransplant distress revealed in this study. Unmatched allogeneic transplant was associated
with greater distress than autologous or matched allogeneic transplants (p = .03). Female
participants experienced more distress than male counterparts (p = .004) and participants
with greater than a high school education reported less distress than those with a high
school education or less (p = .01).
In the review of studies investigating the impact of mood disturbances on the
transplant recipient, it is almost uniform to find studies with small sample sizes, a variety
of transplant types and mixed cell types for the primary cancer diagnosis. In a review
performed by Moser and colleagues (2009), only 22 prospective reports were found
containing at least 20 participants in a 5-year span which addressed the physical,
psychological and social aspects of quality of life for the transplant patient. There appears
to be great opportunity to study the frequency of mood disturbances in the patient
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population, particularly in the immediate post transplant period, and to investigate
interventions beyond drug therapy to assist patients in supporting their emotional
stability.
Relation between fatigue and mood disturbance. BMT patient research has
demonstrated a relationship between two of the variables in this study, fatigue and mood
disturbance. In a relatively early study investigating relations of symptoms in the
transplant population, Gaston-Johansson et al. 1999) surveyed patients with breast cancer
undergoing BMT. The study demonstrated a significant correlation between fatigue and
mood with these 127 patients (r = 0.58, p < 0.001). Molassiotis (1999) also studied
correlations between the symptoms experienced by patients at least 6 months post
transplant. In the participants (n = 91), he found that lack of energy was correlated with
depression (r = 0.59, p < 0.001), psychological distress (r = 0.52, p < 0.001) and
depressed mood (r = 0.45, p < 0.001).
El-Banna and colleagues (2004) studied these two variables in patients with
lymphoma undergoing bone marrow transplant. As with many of the studies, the sample
size was small with 27 participants. This study also utilized the PFS-R instrument (Piper
et.al., 1998) to measure fatigue levels but used The Center for Epidemiologic StudiesDepression Scale (Radloff, 1977) to measure depression rather the broader concept of
mood disturbance. This study found that the fatigue scores, total and subscale, and
depression scores were highest at day 7 post transplant (all p <0.05). Spearmen
correlation between depression and all fatigue scores ranged from 0.851 to 0.929 (p =
0.001 and 0.009, respectively).
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Summary
Nightingale (1859) utilized controllable variables in the environment to facilitate
healing. She promoted light, color and cleanliness to enhance the patient’s recuperation.
The science behind the interaction between light and color on an individual has not yet
been defined in the 21st century. Nightingale used anything within her control to provide
an improved outcome for those receiving care. And it is for this reason she embodies
what nursing has always been. The goal of nursing has always been to improve the
patient experience while improving patient outcomes, whether in the 19th or 21st
centuries.
Roger’s (1980) abstraction of the human interaction with their environment
funnels momentum into just how critical nursing is in the patient’s recovery. The idea
that environment can constantly impact, change and modify the human experience is
pivotal to the idea that light can impact symptomatology. Walling’s (2006) use of
acupuncture as an example of the environment changing the internal functioning of the
human provides one with a concise picture of Rogers’ vision. In emerging research in
psychoneuroimmunology, the Rogerian viewpoint of patient and environment interaction
appears more logical and plausible.
Fatigue and mood disturbances are frequent symptoms experienced by patients
prior to, during and after PBSCT (Andrykowski et al. 2005; Bevans et al. 2008; Carlson
et al. 2006; Coleman et al. 2002). These are internal experiences that patients identify yet
their etiology can only be assumed to originate from the cancer or the treatment applied
to cure it. The application of light as an environmental element in interaction with human
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biochemical processes is plausible but not fully defined or understood. There is evidence
that light plays a part in a multitude of biochemical changes that occur within the inner
workings of physiology. Light as a therapy has a very limited body of knowledge in the
cancer patient population, so the connection between light, fatigue, and mood
disturbances in this population is still a question. The measurement of natural and
ambient light exposed to the patient during the treatment phase of PBSCT has not been
performed.
Nursing defines interventions which make differences in not only the patient’s
experience, but the patient’s outcome. The research on the impact of light on the PBSCT
experience is non-existent, yet there appears to be supportive research to apply it to this
patient population. The vast majority of patients undergoing PBSCT are not in the
position to have multiple options for treatment. Nursing may have the opportunity to
provide supportive interventions which could make the patient feel better and perform
better in the post transplant process. While the use of light as a therapy may not provide a
curative intervention to treat symptoms of fatigue and mood disturbances, it may be used
as an adjunct along with other interventions such as exercise or cognitive behavioral
therapy to aid the patient toward a better outcome.
The following chapter will discuss the design of the study and the measurement
instruments used. It will discuss the sample characteristics and the analysis for the
findings.

CHAPTER THREE
METHODS
This chapter will describe the methods used in this study. A review of the study
purpose and research aims and hypotheses are provided. The study design, sampling
methods, sample characteristics and sample size are discussed. Variables, details of
measurement instruments, data collection and management, data analysis and ethical
considerations are also included.
Study Purpose and Aims
The purpose of this study was to examine the relationship between light exposure
during the immediate post-bone marrow transplant experience, activity levels post
transplant and the perception of fatigue and mood. Light levels had not been studied in
the bone marrow transplant patient nor had the associations between light and fatigue and
mood been explored. Patients undergoing BMT served as the sample population since
they have prolonged inpatient stays and most have moderate to severe fatigue
(Molassiotis, 1999).
Martha Rogers’ (1980) Science of Unitary Human Beings theory provided the
foundational constructs and framework for the study of light exposure and a patient’s
symptoms. The use of light as the independent variable is identified as a component of
the larger environmental energy field. Between the environment and the human energy
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field interaction, light served as a stimulus for pattern change occurring in the human
energy field.
Study Design
This study was descriptive and exploratory, using measures at time points during
the transplant process to determine the relationship between natural and ambient light
exposure to the patient experience during and following the bone marrow transplant.
Since the relations between the selected variables have not been defined, this study acted
as a precursor to investigating light as an intervention within the stated patient
population.
Measurement tools for fatigue and mood provided a way of evaluating the
relationship between the variables. Instruments for fatigue and mood state were
completed by participants at three time points: prior to admission, Day 2 of post
transplant and Day 11 post transplant. Light levels in the patient environment were
measured at two time points using a wrist light meter with memory. The light levels were
measured for a maximum of 48 hours at each time point. The patient’s activities during
study participation were recorded by using a wrist worn activity monitor with memory
(Philips Respironex, 2013). This device was used to count steps taken during two 48 hour
periods. The two data collection time points for light and activity were measured at Day
0-2 of transplant and Day 9-11 of transplant.
Study Site
The research was conducted at Loyola University Medical Center located in
Maywood, IL. It is a teaching, tertiary care, level 1 trauma center with an active bone
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marrow transplantation program. The hospital is licensed for 569 acute care beds with 27
bone marrow transplant beds (15 inpatient, 12 outpatient). Between 2009 and 2013,
Loyola has performed 581 adult bone marrow transplants (BMTinfonet, 2015). It is one
of the largest bone marrow transplant programs in Illinois (National Marrow Donor
Program, 2016).
Sample
Participants approached for participation in this study had all been approved for
bone marrow transplantation for a hematologic non-solid tumor malignancy. As part of
the preparation for transplant, these individuals received full physiological work ups
which included assessment of neurological, cardiac and renal function. It is for these
reasons that participant co-morbidity was not addressed as exclusion criteria. All patients
received the transplant procedure and the majority of their care at either the Cardinal
Bernardin Cancer Center or the Bone Marrow Transplant Unit at Foster G. McGaw
Hospital, both at Loyola University Medical Center. Patients receiving autologous or
allogeneic bone marrow or stem cell transplant were invited to participate.
Inclusion criteria. Participants invited to participate in the study were between
the ages of 18 and 75 and able to understand, read, write and speak English. Participants
between the ages of 18 and 75 were considered eligible. The participants had to be
accepted to receive a bone marrow or stem cell transplant for treatment of leukemia,
lymphoma, malignant myeloma, and precursor conditions to these. Finally, the
participants were expected to receive pre-transplant care and the first 100 days post
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transplant care at Loyola University Medical Center and/or the Cardinal Bernardin
Cancer Center in Maywood Illinois.
Participants were required to have normal mental status and capacity to
understand. They were alert, oriented and able to maintain attention and eye contact
during interview. Speech was assessed to be clear and understandable. Patients had an
intact memory and were able to comply with the study related interviews
Exclusion criteria. Participants receiving a stem cell or bone marrow transplant
for solid tumor malignancies or autoimmune diseases as the underlying condition were
not eligible to participate. Participants who had received a prior transplant for any
condition were not approached to participate. It was believed that patients naïve to the
transplant process would provide more information from the transplant experience and
would not be influenced by a prior transplant experience. Screening for transplant entails
survey of physiologic functions so no subject co-morbidities were addressed in the
exclusion criteria. Presence of co-morbidities such as a low ejection fraction or
significant renal insufficiency could preclude patients from undergoing a bone marrow
transplant.
Sample size estimation. According to Browner, Newman, Cummings, and
Hulley (2001), using a significance level of 0.05 for a two sided hypothesis, a medium
effect size of .30 and a power of .80, a sample size of 85 was projected. An additional
method for determination of sample size required for the current study included power
analysis for the hypotheses (Browner et al. 2001). All of the hypotheses assumed that the
threshold for rejection of the null hypothesis was to be a p value of .05 using a two-tailed
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test. Further, the desired level of statistical power was .80, a level that is generally viewed
as acceptable for exploratory research (Browner et al. 2001). Estimates of effect size in
the power analysis were based on prior research on the relationship between light
exposure and the dependent variables in the present study. Computations of statistical
power were based on the G-Power 3 software package (Faul, Erdfelder, Lang & Buchner,
2007). This software package enabled the investigator to enter specific effect sizes based
on prior research on the relationships under study.
To test hypothesis 1, the bivariate correlations between light levels and measures
of fatigue and mood were examined. Prior research suggested that light levels have a
correlation of approximately 0.3 with these outcomes (Liu, 2005; Partonen & Lonnqvist,
2000). Using this estimate of the effect size (r = 0.3), a sample size of 82 was needed to
attain a power level of .80. For hypothesis 2, bivariate correlations between light levels
and physical activity were computed. While prior studies of the effects of light do not
provide an estimate of effect size specifically for activity, the effect sizes noted earlier in
Chapter 2 for other dependent variables tend to range around .30. Using this figure as an
estimate of the effect of light on activity, a sample size of 82 was needed to attain a
power level of .80 for hypothesis 2. To test hypothesis 3, a multiple regression procedure
was utilized, in which levels of fatigue at defined time points post transplant were
regressed onto two predictor variables: pre-transplant fatigue and cumulative light
exposure. If we assume that the effect size for cumulative light exposure is approximately
as large as the bivariate association between light exposure and fatigue at one time point
(r = .3), then a sample size of 82 cases would be needed to attain a power level of .80. In
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order to provide adequate statistical power for testing all three hypotheses, a sample of 82
was needed. Given the reality of a combined mortality rate between autologous and
allogeneic transplants and attrition, additional patients were enrolled. The ending study
sample size was defined as 90.
Recruitment. It was anticipated that the prospective participants would be
identified primarily by the BMT Coordinator scheduling process. Physicians in the
Section of Hematology and Oncology at Loyola University Medical Center agreed to
allow their patients to be approached for study participation. The preparation for the
transplant admission was tracked by the BMT coordinators; this schedule was shared
with the investigator on a weekly basis. All participants and their primary care givers
were required to attend a 4-hour class to prepare the patient for the transplant as well as
to prepare the primary care givers to handle outpatient care and needs. Once the patient
was on the schedule for either class attendance, line placement or plasmapheresis, the
investigator met them and an explanation of the study was provided. A copy of the
consent was provided to any participants who indicated interest in participating in this
study. The participant could sign at the first meeting with the investigator or the patient
could sign at a later date but signature was required prior to admission for transplant. As
the trial went on, accrual was slow. With the approval of Cancer Center Administration
and the Cancer Research Office, the BMT Research RN also began introducing the study
to prospective participants as she was discussing other studies that the participant might
wish to participate. The BMT Research RN would meet with all transplant patients prior
to hospitalization to educate them on research trials for which they were eligible for.
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Approximately 6 months into the trial with accrual continuing to be slow, the
investigator was also invited to present the trial to all patients attending the BMT Patient
& Caregivers Class. At that time a copy of the consent was provided to all BMT patients.
Either the investigator or the BMT Research RN would follow up with patients regarding
their signed consent and willingness to participate. This approached assisted in
connecting the investigator to the prospective participants however accrual continued to
be slow.
Variables
Independent variable. Light was the independent variable within this research.
Conceptually, light was defined as “a form of energy that makes it possible to see things;
the brightness produced by the sun, by fire or by a lamp” (Merriam-Webster, 2015). An
operational definition for light was an electromagnetic radiation that is visible and
perceivable by the normal human eye made up of colors between red and violet in
varying frequencies and wavelengths (FreeDictionary, 2015). The measurement of light
was accomplished through the use of the wrist worn device. This wrist worn meter was
programmed to take light readings at defined intervals with a memory capable of holding
multiple days of data. Light was described in terms of lux for intensity. Light exposure
was derived from artificial interior devices (ambient light) or from natural sunlight
coming in through doors or windows within the hospital.
Light exposure was measured by Philips Actiwatch 2 meter (Philips Respironex,
2013). It is designed in the style of a wrist watch and can take continual light readings at
defined time intervals. Both ambient and natural sun light were captured. Light exposure
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was measured for 48 hours: Day 0 (date of actual transplant) to Day 2 and Day 9 to Day
11 post transplant. Light was reported as one cumulative number in lux for each
measurement period.
Dependent variables. The defined dependent variables for the study were
fatigue, mood, and activity. Fatigue was conceptually defined as a subjective experience
encompassing weariness, tiredness or lack of energy (Dimeo, 2001). Operationally,
fatigue was defined in the scores on the 22 item Piper Fatigue Scale-Revised (PFS-R)
(Piper et al. 1998).
Within this cancer patient population, research is also being performed to define
“cancer related fatigue” (CRF) with the development of specific criteria which would
differentiate it from fatigue associated with other illnesses. CRF is described as persistent
subjective sense of tiredness related to cancer treatment, it is based on the patient’s
perception and it interferes with the person’s normal functioning (Piper & Cella, 2008).
This work on CRF is evolving in the literature and is not universally measured with a
specific tool. For this reason, fatigue was addressed as a variable that is present within the
defined subject population.
The second dependent variable was that of mood. Conceptually, mood was
defined as the emotional state of an individual's mind (FreeDictionary, 2011) and was
reflective of how the person was experiencing the feeling at a particular point in time.
Mood may have many feelings and the feelings can be transient. Psychological distress
may also be considered as a synonym for mood. Operationally, mood was defined by the
scores on the Profile of Mood States-Short Form (POMS-SF) (Shacham, 1983).
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The third dependent variable was physical activity. Conceptually, physical
activity was defined as the independent movement of the body performed by the
individual. Operationally, physical activity was measured in quantity of steps taken using
a Philips Respironex Actical (Philips Respironex, 2013) which will be detailed in the next
section.
Measurement Instruments
Light. In the original plan for this research, light was to be measured using a
digital lux/footcandle meter which was advertised to measure up to 100,000 lux. The
ExTech Model LX-1108 distributed by D.A.S. Distribution, Inc. located in East Granby,
CT was marketed as having data logging capability and computer interface. It was
programmed to take light readings every 30 minutes for a 48-hour period and was used
on the first two patients enrolled in the study. At the end of the 48-hour period, the
instrument only provided intermittent readings and not a sustained data log. After
working with the company, this equipment was abandoned. A protocol amendment was
submitted to use the Actiwatch 2 light meter.
For the remainder of the study, light exposure was measured using a digital lux
meter which measures up to 100,000 lux. Actiwatch 2 was used as the light measurement
with data logging capability and computer interface. This model had a built in clock with
date and time stamp and data storage recording intervals from 1 second to 60 minutes
based on programming. It is distributed by Philips, Inc. located in East Granby, CT. The
Actiwatch 2 is manufactured by Philips Respironex using a silicon photodiode light
sensor. The device is re-chargeable with a battery life of up to 30 days set at 1 minute
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intervals. The light measurement is provided in lux with an illumination range of 5100,000 lux. The device has an accuracy of 10% at 3000 lux. It is marketed as having
moisture protection with water resistance at 1 meter for 30 minutes. It is resistant to dust,
water, heat, perspiration and cold. It works with Windows 2000 operating systems and
was set to take light readings every minute for a 48-hour interval. Participants were
instructed to wear the meter on the wrist for the defined time interval. Wrist devices were
disinfected with antibacterial wipes and actual bands were removed and sterilized
between patients. This device has been tested in multiple settings validating its reliability
in the measurement of lux exposure (Long, Palermo, & Manees, 2008; Osse, Joke, Tulan,
Hengeveld & Bogers, 2008; Wener, Luciano, Guyer & Jenni, 2008).
The Actiwatch 2 was placed on the participant’s wrist on Day 0 and removed on
Day 2 accounting for 48 hours of light measurement. The Actiwatch 2 was placed on the
participant’s wrist on Day 9 and removed 48 hours later on Day 11. Participants were
instructed to keep the wrist band fully exposed for maximum accuracy in light
measurement.
Fatigue. The Revised Piper Fatigue Scale (PFS-R), developed by Piper, Dibble,
Dodd, Weiss, Slaughter et al (1998) was used to measure fatigue. The instrument consists
of 22 items, asking the subject about their current state of fatigue in the last 1 to 2 days. It
was derived from the original Piper Fatigue Scale (PFS) (Piper, Lindsey, Dodd,
Ferketich, Paul et al. 1989) which has 42 items. The original and revised tools have been
used primarily with breast cancer patients (Demiralp, Oflaz, & Komurcu, 2010);
however, these tools have also used with other oncology patient populations (Alt, Gore,
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Montagnini, & Ng, 2011; Battaglini et al. 2009; Berger, 1998; Berger, Grem, Visovsky,
Marunda & Yurkovich, 2010; Berger & Higginbotham, 2000; El Banna, 2004; GastonJohansson et al. 1999; Piper et al., 1998; Schneider & Hood, 2007). While its use in nononcology conditions is limited, it has been used in female patients with benign breast
disease (Andrykowski, Curran, & igLhtner, 1998) and care providers of cancer patients
(Gaston-Johansson et al. 2004). It has been translated and validated in multiple
languages including Portuguese (dos Santos, Mota, & Pimenta, 2009; Lamino, Mota, &
Pimenta, 2011), Italian (Giacalone et al, 2010; Annunziata et al., 2010), Chinese (Liu &
Yuan, 2011), Greek (Lavdaniti, Patiraki, Dafni, Katapoki, Papthanosoglou &
Sotiropoulou, 2006), and Swedish (Ostlund, Gustavvsson & Furst, 2007) among others.
The tool has one overall score and 4 subscales scores: behavioral/mood (6 items),
sensory (5 items), affective (5 items), and mental/cognition (6 items). The
behavioral/mood subscale relates to the severity, distress and degree of disruption that
fatigue has on the subjects’ activities of daily living. The sensory subscale relates to the
subjective physical symptoms of fatigue. The affective subscale focuses on the emotional
attributes the subject assigns to the fatigue experience. Lastly, the mental/cognition
subscale addresses the mental and mood states of the subject (Clark, 2006). Items are
scored in a Likert type scale format from 0 being no distress or none to 10 being a great
deal or significant distress.
Subscale mean scores are calculated by summing the individual items related to
that subscale and dividing the number of items in the subscale/total scale to be consistent
with the 0-10 scaling. Mild symptoms are defined as 0-3.99, 4-6.99 for moderate
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symptoms and severe as 7-10. The tool takes about 2-5 minutes to complete. Adult cancer
patients have found the tool easy to use (Berger et al. 2009).
In Piper’s original study, content and face validity of the PFS were determined
through analysis by an expert panel as well as through an extensive literature search
(Piper et al. 1989). In the revised tool, three of the original dimensions were retained and
a cognitive/mental dimension was added (Piper et al. 1998). Similar to the original PFS,
the PFS-R measures the multidimensional fatigue experience. Convergent validity has
been established with the Fatigue Symptom Checklist (r = 0.55) (Whitehead, 2009). It
has been correlated with the Symptom Experience Report (SER) subscales: SER-Weak (r
= .66) and SER-Tired (r = .75) (Andrykowski, Brady & Hunt, 1993). An exploratory
factor analysis found strong support for construct validity in the behavioral/severity and
affective meaning subscales (Clark et al., 2006). Concurrent validity between the PFS-R
and POMS-SF Fatigue subscale was established with an r = 0.53 to 0.65 (Giacolone, et
al. 2010). The tool has convergent and discriminate validity with the POMS-SF (Piper et
al. 1998). Criterion validity has been established between the PFS-R and
Multidimensional Fatigue Index (MFI) (Smets, Garssen, Bonke, & DeHaes, 1995) with
correlations between MFI-general fatigue subscale and MFI-physical fatigue with the
four PFS-R subscales respectively (r = 0.62-0.84; r = 0 .56-0.81). Dagnelie and
colleagues (2006) also found criterion validity between the PFS-R Total and the MFI
Subscale General Fatigue (Pearson’s correlation of 0.84; p < 0.01). Construct validity
was evaluated between the MFI and PFS-R in breast and lung cancer patients.
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Piper and colleagues (1998) tested the reliability of the PFS-R with 382 breast
cancer survivors achieving excellent Cronbach’s alphas for the total score and the four
subscales from .92 to .95: sensory = .959, affective = .954, cognitive/mood = .926,
behavioral/severity = .920 and total = .966. Factor analysis was performed to determine
items to be kept. The standardized alpha for the entire PFS-R is 0.97. Test-retest
reliability was performed with a .98 correlation (So et. al. 2005) and Pearson’s correlation
coefficients of 0.63 and .91 between subscales (Giacalone et al. 2010). Internal
consistency of the PFS-R in a variety of cancer patient populations has been established
with Cronbach’s alphas of .85 to .97 (Piper et al. 1998; Gledhill, Rodary, Mahe & Laizet,
2002; Gaston-Johannson et al. 1999; Schneider & Hood, 2007).
The PFS-R has been widely used in evaluating fatigue in breast cancer patients
prior to chemotherapy, during treatment and post treatment with good Cronbach’s alpha
scores of .92 to .95 (Berger & Higginbotham, 2000; Andrykowski, Curran & Lightner,
1998). It has been able to detect significantly different levels of fatigue with only a 7point difference in mean scores (p<0.05) (Andrykowski, Curran & Lightner, 1998). Total
fatigue scores correlate with three of the PFS-R subscales (r > .87). The tool has been
used with bone marrow transplant patients and their caregivers with Cronbach’s alphas of
.83-.90 (El-Banna, Berger, Farr, Foxall, Friesth, et al. 2004; Gaston-Johannson et al.
1999; Gaston-Johansson et al. 2004).
The PFS-R was completed by the participant at three time points. A baseline
measure was taken prior to the participant’s admission into the hospital for the transplant
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procedure. The participant completed the PFS-R at Day 2 and again on Day 11 at the
time the wrist monitors, the Actical and the Actiwatch 2 were removed.
Mood Disturbance
The Profile of Mood States short form (POMS-SF) (Shacham, 1983) was used to
measure the mood state of the participants. It was derived from the original Profile of
Mood States (POMS) created by McNair, Lorr & Droppelman (1971). It is important to
note that there are several shortened versions of the POMS from the original 65 item
format. Shacham (1983) developed a 37 item version of the POMS-SF which utilizes five
of the original mood states: tension-anxiety, depression-dejection, vigor-activity, fatigueinertia and anger-hostility. The sixth mood state on the tool is confusion-bewilderment.
The POMS-SF has been used extensively in the cancer patient population (Tfijsburg, Van
Knippenberg & Rijpma, 1992) as well as with healthy subjects and subjects with a
variety of conditions.
Using the same Likert type scale as POMS, subjects completing the POMS-SF
can select from 0 (none or not at all) up to 4 (the most or maximum). The maximum
score for any one mood state is 4 as questions in each subscore are added and then
divided by the number of items for that mood state. The higher the score, the more
negative the mood state. The composite score of the tool is termed the Total Mood
Disturbance (TMD) and is calculated by adding the individual scores for Tension,
Depression, Anxiety, Fatigue and Confusion subscales and subtracting the Vigor subscale
score. The maximum TMD score is 16.
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In developing the shortened version, Shacham (1983) eliminated 2 to 7 items
from each subscale without decreasing the internal consistency. In the process, the
Confusion subscale and Tension subscale saw improved internal consistency coefficients.
The tool was validated with 83 participants with a cancer diagnosis however the
management of these patients was focused on pain management rather than disease
treatment. The correlations in the subscales between the original POMS and the POMSSF were all high, (r > .95) with the TMD of .99. There was no factor analysis in the
original work performed by Shacham (1983).
Curran and colleagues (1995) tested psychometric properties of the POMS-SF as
compared with the original POMS. Four of the six patient participant groups included
BMT survivors (n=210), BMT candidates (n= 85), breast cancer patients (n=46) and a
healthy group of subjects (n= 76). Of most interest to the current study, BMT candidates
and BMT survivors demonstrated a high internal consistency in the scores and TMD of
the POMS-SF and POMS. In fact, it was felt that the POMS-SF had stronger internal
consistency than the original tool. The BMT candidate TMD score correlated well with
all subscale scores between the POMS and POMS-SF (r > 0.78). In the BMT survivor
group, correlation between TMD score and subscale scores was also high (r > 0.80)
between the two tools.
Baker (et al., 2002) evaluated the internal consistency and validity of the POMSSF with 428 cancer patients awaiting bone marrow transplantation. The Cronbach’s alpha
ranged from .78 to .91 for the six subscales and overall TMD score. This study also
included a confirmatory factor analysis which supported the six factor interpretation of
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the POMS items to the POMS-SF. Convergent and discriminant validity was shown
through correlations made between POMS-SF and other tools. The CES-D correlated
with both the POMS-SF TMD and the POMS-SF-Depression subscale at .63 and .63
(p<0.001). The researchers projected a positive correlation between the POMS-SF -Vigor
and the Bradburn positive affective scale (Bradburn & Caplovitz, 1965). This was
validated with an r = .53 (p < 0.001). In the same light, the POMS-SF fatigue subscale
would not be expected to correlate with the Bradburn positive affective scale. This was
consistent with the weak, negative relationship found between these two tools (r = -0.17,
p < 0.001).
Baker, et al. (2002) assessed convergent and discriminant validity of the POMSSF subscales as related with other measures of psychological distress. He proposed that
the Depression subscale of the POMS-SF would correlate highest with the CES-D, which
it did with an r = 0.63. The researchers also expected that Fatigue and Vigor subscales
would correlate highest with two measure of physical functioning – the MOS Physical
Functioning Scale (Aaronson et al. 1965) and the self-rated Karnofsky Performance
Status (KPS) scale (Karnofsky & Burchemal, 1949). This was also confirmed with the
Vigor subscale having the highest correlation with these two instruments (Vigor and
MOS, r = .42; Vigor and KPS, r = .39). He also proposed that the Fatigue subscale would
have the least correlation with the MOS and KPS scale which it did (Fatigue and MOS, r
= -.42; fatigue and KPS, r = -.40) (p < 0.001). While the tool has been used widely with
breast cancer patients (Von Ah et al. 2008), it has also been used in patients with
gynecological cancer (Gould, Brown & Bramwell, 2010), prostate cancer (Bailey,
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Mishel, Belyea, Stewart, & Mohler, 2004), and mixed tumor types (Cunningham,
Edmonds, Phillips, Soots, Hedley et al. 2000; Silver-Aylaian & Cohen, 2001).
The POMS-SF was completed by the participant at three time points. A baseline
measure was taken prior to the participant’s admission into the hospital for the transplant
procedure. The participant completed the POMS-SF at Day 2 and again on Day 11 at the
time the wrist monitors, the Actical and the Actiwatch were removed.
Activity. In the original protocol, activity was going to be documented through a
self-reported diary kept by each participant. When the search for a new light meter
ensued, it was decided that activity would also be measured by a device as well. The
Actical activity monitor, manufactured by Philips Respironex, Inc., was used to measure
activity. It is a 1” x 1.5” titanium accelerometer which can be worn at waist, wrist or
ankle. For the purposes of this study, the device was worn at the wrist, preferably on the
arm not used to push intravenous pole while up. It uses a CR 2025 lithium coin battery
and has a 32mb memory (Philips Respironex, 2013). The maximum recording time is
dependent on the programming but expected to be </= 12 days. It is advertised as
waterproof at 1 meter for 30 minutes. The device was programmed to measure number of
steps for a 48-hour period. It syncs with Windows 7 operating system when linked with
an ActicReader interface device and a computer.
The Actical was placed on the participant’s wrist on Day 0 and removed on Day 2
accounting for 48 hours of activity measurement. The Actical was placed on the
participant’s wrist on Day 9 and removed 48 hours later on Day 11. Participants were
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instructed to push their IV pole with the opposite hand from the Actical placement for
better measurement of steps via arm movement.
Additional data. The medical record of the patient was accessed for data
retrieval. Specific physiologic data were extracted from the medical record for the three
data collection times. This information included age, gender, type of transplant, type of
underlying malignancy, date of original diagnosis, height, weight, ethnicity, KPS and
hematology laboratory results. These data were collected for additional correlational
investigation. The complete blood count and the KPS may provide additional information
about the participant’s activity tolerance. In addition, the KPS has established correlation
with the POMS-SF Vigor and Fatigue subscales.
Research Procedures
After the approval by the dissertation committee, the research proposal was
submitted to the Loyola University Medical Center IRB for review and approval.
Participants were required to sign the IRB approved informed consent and were provided
with a copy. The participants were educated on the requirements for participation, which
emphasized that participation could end at any time, upon their decision, without any
consequence to their care and treatment.
After the protocol had been approved by the designated IRBs, meetings were held
with nursing staff, BMT Nurse Practitioners and Hematologist to discuss eligibility
requirements and critical elements of protocol. Potential participants were identified by
the BMT Coordinators responsible for scheduling all critical elements of the patient’s pre
transplant work up. The majority of potential participants were met during the Patient &
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Caregiver Class held at the Cardinal Bernadin Cancer Center. All transplant patients and
their caregivers were required by the transplant program to attend this 3-hour educational
session to prepare them for the post discharge period.
If the participant was interested in participation, the informed consent document
was reviewed, including a description of the study, the risks and benefits, confidentiality
issues and a statement indicating that participants could withdraw from participating in
the study at any time with no consequence. Once the potential participants were screened
and confirmed to meet eligibility criteria, the informed consent process was completed.
All information obtained from the participant or their respective medical record
was secured by the investigator with only the study roster and the participant’s signed
informed consent containing the name and medical record number. All other documents
used for data collection were de-identified.
Data Collection and Management
Participants were identified on study related documents using first and last initials
and a unique identification number. One master study roster matching participant name
and identification number was kept in a locked and secured location. Participants
completed measurement tools, PFS-R and POMS-SF, prior to admission, on Day 2 and
Day 11. During Day 0-2 and Day 9-11 post transplant, light levels and activity were
monitored for 48 hours. Participants were instructed to wear the Actical activity monitor
and the Actiwatch 2 monitor continuously on their wrist for the 48 hour period but were
requested to remove both devices when taking the twice daily tub bath. For the Actical
monitor, participants were requested to push the IV pole with the opposite hand in order
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to gain better accuracy. For the Actiwatch, participants were requested to keep the wrist
monitor uncovered by clothing to gain the maximum recording of light exposure. Contact
with the participants took place in the Cardinal Bernardin Cancer Center and the Loyola
University Medical Center.
At each time point during the participant’s post transplant, the instruments were
administered for completion and immediately retrieved. Data were collected using patient
completed questionnaires and downloading data from the Actical activity monitor and the
Actiwatch 2 light monitor. Data downloaded from the two meters was done for 48 hour
periods during Day 0-2 and Day 9-11 post transplant. The rationale for this data
collection at two time points was to document changes in light levels and activities as the
patient began bone marrow engraftment.
All study related documents were coded with the participant number were locked
in a file cabinet of the investigator.
Data Entry, Cleaning, and Analysis
Data were entered into and analyzed using SAS Statistical Software ®. All data
entry were doubled checked for accuracy by an independent reviewer at each data entry
point. Random review of data with verification of computer entered measures was
performed throughout the data collection period to ensure accuracy. Data analysis for
Aim 1and Aim 2 included using Pearson Product Moment Correlation and regression
analysis with an alpha of 0.05. Cross sectional correlations between light levels and
measures of the dependent variables were conducted at each of the following
measurement points: prior to admission, Day 0-2 post-transplant and Day 9-11 post
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transplant. Data analysis for Aim 3 and testing of Hypothesis 3 was performed using
multiple regression analysis at an alpha of .05.
Considerations
Risk benefit ratio to participants. The BMT patient had no interventions
imposed as a result of their participation in this study. The only identifiable risk to the
patient was the disclosure of personal protected health information. This risk was
mitigated through document control including locking all study related material in locked
cabinets in the home of the investigator. This risk was also mitigated by linking medical
record data with only the assigned patient code. Participants were informed that they
could end their participation at any point during the study. Any data that were collected
from the participant’s medical record were recorded only once on study forms with only
the participant’s initials and the three-digit participant study number. There were no
direct benefits for participation to the subject. A higher level benefit was the contribution
to the body of knowledge regarding the transplant experience.
Ethical considerations. The study was submitted to the Loyola University
Medical Center IRB for review and approval to ensure that elements for protection of
human subjects were present. Participants were fully informed of the specifics of the
research prior to signing the IRB approved informed consent document. Participants also
verbalized the understanding that withdrawal from participation could occur at any time
point during the study without consequences or impact to the course of treatment.
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Summary
In this chapter, study related procedures were described including protocol
approval, study procedural requirements, patient accrual process and data
collection/control. In chapter 4, the results of this study are presented.

CHAPTER FOUR
RESULTS
The purpose of this study was to test the hypotheses that light levels have a
relationship to the levels of fatigue and mood a patient experiences while undergoing a
bone marrow transplant. A secondary purpose was to investigate any relationship
between light level exposure and physical activity. In addition, it meant to determine the
relationship between cumulative light levels and fatigue. The aims of the study were as
follows: (1) to establish the relationship between natural and ambient light exposure and
a bone marrow transplant patient’s level of fatigue and mood state during hospitalization,
(2) to establish the relationship between the level of light exposure and a bone marrow
transplant patient’s physical activity during transplant hospitalization, and (3) to establish
the relationship between the cumulative level of light exposure with fatigue in a patient
during the bone marrow transplant process.
Recruitment Information
Ninety patients were consented and enrolled in this study (See Figure 1 for
enrollment diagram). Participants were only consented if they met study criteria. Of the
90 participants, 4 participants were initially excluded due to withdrawal of consent (n=2,
2%) or failure to provide baseline information at the beginning of the study (n=2, 2%).
Eighty-six participants (95%) completed the baseline measures. After the baseline
measurement period, 4 participants (4.65%) withdrew consent and 4 participants (4.65%).
94
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were too ill to continue. When participants stated they did not wish to continue, it was
primarily due to them feeling unwell. For participants that were assessed as too ill to
continue, it was due to change in condition which prevented them from participating.
Changes in condition included decreased level of consciousness or endotracheal
intubation. After the baseline measures had been collected, 2 participants (2.32%) expired
prior to getting to transplant. Since the participants were severely immunocompromised,
any symptoms of illness by the investigator would prohibit her from seeing the
participants for monitor application or completion of measurement tools. This occurred
once prior to the Light Time 1 measurement period (n=1, 1.16%).
For Light Time 1 measurement, 74 (82.2%) participants were included. Prior to
Light Time 2 measurements, 6 participants (8.1%) were discharged home prior to Day 9,
5 participants (6.75%) declined to continue participation, 1 participant (1.35%) was too
ill to continue, and 1 participant’s data was not retrieved due to investigator illness (n=1,
1.35%). There were only 61 (67.7%) participants available for Light Time 2
measurement period. One participant (1.35%) experienced cardiopulmonary arrest during
this measurement period so data were incomplete. This meant that complete study data
were only retrieved for 60 of the 90 consented participants or 66.6%.
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Figure 1. CONSORT 2010 Flow Diagram.
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Missing Data
Missing data were most frequently due to the participant not feeling well enough
to complete the instruments or not inclined to wear wrist devices. If completed by the
participant, the POMS-SF and PSF-R were checked for completeness prior to leaving the
patient. Missing items were addressed verbally with the participant at that time. There
were limited issues with incomplete instruments as the investigator addressed missing
items with participants at time of retrieval. Missing data also resulted from malfunction
of monitoring devices or misuse by the participant. At the beginning of the trial, different
devices were employed. After the first two participants were enrolled, it was identified
that the light monitoring equipment was not performing as advertised so equipment was
changed out to the present equipment identified in the study. Two participants failed to
remove the wrist devices for the twice daily tub baths. This resulted in the failure of the
devices to adequately record data. These monitors were sent to the manufacturer but data
were not able to be retrieved. If the participant did not feel well enough or so inclined to
participate in the Day 0-2 activities, they were asked if they could be re-approached for
the Day 9-11 activities. Hence some participants might not have completed Day 2
measures but did complete Day 11 measures. Participants were well aware that they
could withdraw at any time. For the most part, a participant’s refusal to continue in the
trial was directly related to how unwell they felt when the investigator visited them in
hospital to place the wrist meters on or to have the participant complete the tools (n=9,
10%). There were participants that experienced a change in condition which prevented
them from carrying out all study requirements (n=5, 5.5%). There were 3 (3.33%)
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participants that expired during some portion of their participation in the trial. Six
participants (n=6, 6.6%) were discharged home prior to the Light Time 2 measurements.
Equipment failure with one participant (1.11%) prevented completion of all measurement
points. Because participants were immunocompromised, investigator illness prevented a
portion of data collection on 2 participants. As per the protocol, no drop outs were
replaced with new participants.
Characteristics of Overall Sample
The majority of the sample was male (n=62, 68.8%), Caucasian (n=78, 86.6%)
and over age 60 (n=29, 44.3%). Demographics of the participants are provided on Table
1. The sample of participants was not diverse as only four African Americans and eight
Latinos were enrolled (4.4% and 8.8% respectfully). The majority of the participants
(n=70, 79.5%) were receiving a transplant for either multiple myeloma, lymphoma or
AML. Multiple myeloma made up the largest group of participants by disease type
(n=29, 32.9%). The second most frequently diagnosis was that of lymphoma (n=24,
27.3%) followed by AML (n=17, 19.3%).
Autologous transplants are treatment options for multiple myeloma and
lymphomas while allogeneic/cord blood transplants are treatment choices for the
leukemias. Because of this, autologous transplants were planned for 54 (61.4%) of the
participants while 34 participants (38.6%) were receiving allogeneic or cord blood
transplants.
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Table 1. Participant Demographics
N

%

Gender
Male
Female

N (Total = 90)
62
28

68.8
31.1

Age
18-40 years
41-60 years
>60 years

N (Total = 88)
15
34
39

17.0
38.7
44.3

Race
Caucasian
Hispanic
African-American

N (Total = 90)
78
8
4

86.6
8.8
4.4

Diagnosis
Multiple Myeloma
Lymphoma
Acute Myelogenous Leukemia
Acute Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Myelodysplastic Syndrome
Other

N (Total = 88)
29
24
17
5
5
4
2
2

32.9
27.3
19.3
5.7
5.7
4.5
2.3
2.3

Transplant Type
Autologous
Allogeneic
Allogeneic Sibling
Cord Blood

N (Total = 88)
54
29
3
2

61.4
31.8
3.4
2.3

KPS attempts to define the level of function the BMT patient has. This is most
frequently assessed by the Hematologist or their mid-level provider. In this study,
consistent data capture of the KPS was prevented by lack of documentation in the
medical record. For baseline KPS measures, it was only found in the documentation for
78 participants (86%). For Light Time 1 and Light Time 2 measures it was found in the
documentation for 50 (67.56%) and 43 (70.49%) participants respectively. The mean for
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KPS (82.6, S.D.9.7) at baseline was slightly higher than the mean KPS for Light Time 1
(74.8, S.D.6.6) and Light Time 2 (74.2, S.D. 8.2) measurements. A KPS of 80% differs
from 70% in the level of effort the patient must exert to continue with activities of daily
living. While a patient with a KPS of 70% would be able to care for his/her individual
needs, it would be difficult for the patient to carry on with normal pre-illness activity or
work. With a KPS score of 80%, the patient would be able to maintain normal activities
but with much greater effort exerted. KPS data can be seen in Table 2.
Table 2. KPS Status Score
KPS
Baseline (n = 78)

M (SD)
Min
Max

82.6 (9.7)
60
100

Time 1 (n = 50)

M (SD)
Min
Max

74.8 (6.6)
50
100

Time 2 (n =4 3)

M (SD)
Min
Max

74.2 (8.2)
60
90

Biomarkers retrieved during the study included completed blood count results.
These data were retrieved because of the relationship between activity tolerance and
anemia. As the hemoglobin and hematocrit decrease, the person’s ability to tolerate
activity declines, and subsequent fatigue can be experienced. As expected, baseline
results were mostly within normal range and as the participant received pre-transplant
chemotherapy, those numbers fell. The most dramatic shift in the results is that of the
WBC which was well below normal at Time 1 measurements but demonstrated a level of
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recovery by Time 2 measurements. The participant’s blood product transfusion
experience was not part of the data collection. The changes or lack of significant changes
may be reflective of transfusion support provided between the data collection tines. These
results can be seen in Table 3.
Table 3. Biomarkers
HGB(13.5-17.5g/dL) HCT(36-50%) WBC(3.5-10.5K/MCL)
Baseline

n
M (SD)
Min
Max

86
11.1 (1.8)
6.4
14.3

85
32.6 (6.2)
11
43.9

86
11.1 (16.9)
0.6
83.5

Time 1

n
M (SD)
Min
Max

74
9.8 (1.3)
7.4
13.9

74
28.6 (4)
20.8
41

74
1.4 (1.4)
0.1
7

Time 2

n
M (SD)
Min
Max

60
9.2 (1)
5.3
12.9

60
26.5 (3.1)
14.2
36.1

60
3.1 (2.9)
0.1
11.8

The light measures were recorded from Day 0 (day of transplant) until Day 2
comprising 48 hours of data. This is identified as Light Time 1. The second collection
period was from Day 9 until Day 11for 48 hours and this is identified as Light Time 2.
The data for cumulative light exposure is displayed in Table 4. Light Time 1 lux was
smaller than Light Time 2 with greater variation in the maximum and minimum values.
It would be expected that participants who performed more activity outside of the
hospital room would receive a greater amount of light exposure by virtue of the brighter
lighting in the halls than in the interior of the inpatient room. There were significant
correlations between all three light measures. Light measures taken at Light Time 1 were
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moderately correlated with Light Time 2 (r=.32, p=0.02. These can be seen in further
detail in Table 5.
Table 4. Light Exposure
Lux (in
thousands)

a

Time 1 (n = 67)
Day 0-Day 2

M (SD)
Min
Max

113.39a (95.17)
9.15
428.71

Time 2 (n = 56)
Day 9-Day 11

M (SD)
Min
Max

127.28* (130.76)
6.57
628.32

Mean for total light exposure for 48-hour period

Table 5. Light Exposure Time 1 and Time 2

Light
Time 1
Light
Time 2

r
p
n
r
p
n

Light
Time 1

Light
Time 2

Light
Total

1

0.32
0.02
51
1

0.78
<.0001
51
0.85
<.0001
51

66
0.32
0.02
51

55

In the POMS-SF Total scores, the lowest mean was seen at baseline measures
(2.41, S.D.3.65) indicating the least amount of negative mood at the beginning of the
transplant. At Time 1 measure, the POMS-SF Total was at its highest (4.13, S.D. 3.74).
These numbers were not indicative of a negative mood state as the POMS-SF Total
maximum score is 16.
The Tension-Anxiety Subscale mean was lowest at Time 2 (0.85, SD 0.85). The
Tension-Anxiety Subscale mean for Baseline and Time 1 measurement periods were the
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same at 1.11 (SD=0.97 and 0.85 respectively). One could assume that anxiety would be
highest at the beginning of the transplant process, with so many unknowns about patient
response to treatment.
The Depression-Dejection Subscale mean was lowest at Baseline (0.52,
SD=0.73). The mean for this subscale at measurement point Time 1 was the highest
(0.66, SD=0.73). There was only 0.06 difference between the means at Time 1 and Time
2 measurement point (Time 2: 0.60, SD=0.76). It could be anticipated that the longer the
patient was hospitalized, the greater the depression would be however the data show a
minimal difference in scores between the two time periods.
The Anger-Hostility Subscales was lowest at Baseline (0.49, SD=0.76). Means
for Time 1 and Time 2 measurement points were the same at 0.52 (SD=0.70 and 0.69
respectively).
The Vigor Subscale was lowest at Time 1 measurement point (1.19, SD=0.78)
and highest at Baseline (1.57, SD=0.97). This would mirror the escalation of fatigue as
the patient moves through the transplant process. There is a slight increase in the mean at
Time 2 measurement when the blood counts should be increasing as the bone marrow
engrafts resulting in improved activity tolerance.
The Fatigue-Inertia Subscale has the lowest mean at Baseline measurement time
point (1.32, SD=1.05). Fatigue appears to increase at Time 1 measurement (2.04,
SD=1.05) to its highest measurement of the three time points. This would correspond to
the measurement taken closest to the date of the actual transplant. At Time 2
measurement, there is a small decrease in the fatigue mean (1.84, SD=1.23)
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Finally, the Confusion-Bewilderment Subscale has the lowest mean occurring at
Time 2 (0.67, SD=0.82). There is very little difference between the means obtained at
Baseline and Time 1 measurement (0.72, SD=0.72 and 0.73, SD=0.75 respectively). One
might expect an increase in this subscale at Time 2 as the patient is preparing for
impending discharge, which involves a lot of planning and information exchange. The
data do not follow this assumption as there is very little numerical difference among
scores at the three time points. Table 6 displays all the POMS-SF Total and Subscale
scores.
The PFS-R Total mean was lowest at Baseline (3.58, SD=1.99) and was highest at
Time 1 measurement period (4.19, SD=1.79). Each PFS-R Subscale has a maximum
score of 10. Mild to moderate fatigue would score between 0 and 6.99. All of the PFS-R
Total and Subscale mean scores fell into the mild (0-3.99) to moderate (4.0-6.99) fatigue
range. None of the mean scores on the PFS-R Total Score or subscales at any of the three
measurement time points reached the level of severe fatigue. The vast majority of the
means saddled closely between the upper limits of mild and lower limits of moderate
distress as it related to fatigue.
The Behavioral-Severity Subscale had the lowest mean at the Baseline
measurement period (3.35, SD=2.83) and the highest mean occurred at Time 1
measurement period (4.08, SD=2.47). This subscale measures the patient’s perception of
degree to which the fatigue is disrupting their ability to perform activities of daily living.
The scoring does reflect the expectation that fatigue is greatest surrounding the
transplant.

Table 6. POMS-SF Total and Subscale Scores

Baseline
(n=85)

M (SD)

Time 1
(n=73)

M (SD)

Time 2
(n=60)

M (SD)

Min
Max

Min
Max

Min
Max

POMS-SF
total

Tensionanxiety

Depressiondejection

Angerhostility

Vigor

Fatigue-inertia

2.41 (3.63)

1.11 (0.97)

0.52 (0.73)

0.49 (0.76)

1.57 (0.97)

1.32 (1.05)

-3.06
12.48

0
3.33

0
2.88

0
3.28

0
4.00

0
3.60

3.92 (3.58)

1.11 (0.85)

0.66 (0.73)

0.52 (0.70)

1.19 (0.78)

2.04 (1.05)

-2.57
12.88

0
3.50

0
2.75

0
3.33

0
3.17

0
4.00

3.39 (4.02)

0.85 (0.85)

0.60 (0.76)

0.52 (0.69)

1.21 (1.00)

1.84 (1.23)

-3.60
15.74

0
3.50

0
3.13

0
2.86

0
4.00

0
4.00

Confusionbewilderment
0.72
(0.72)
0
3.80
0.73
(0.75)
0
3.60
0.67
(0.82)
0
3.60

Note. Time 1= Day 0-Day 2; Time 2 = Day 9-Day 11.
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The Affective Meaning Subscale had the lowest mean occurring at Baseline (3.48,
SD=2.48) and the highest mean at Time 2 measurement (4.12, SD=2.63). This scale
reflects the emotional attributes that the patient assigns to the fatigue experience.
Certainly the Time 2 measurement point would be at the point where discharge planning
is very active and this may reflect the patient’s emotional concerns about the fatigue they
feel.
The Sensory Subscale had its lowest mean at Baseline (4.28, SD=2.40) and its
highest mean at Time 1 (5.05, SD 2.17). This subscale reflects the subjective physical
symptoms of the fatigue the patient perceives. One would expect that the highest mean
would be associated more closely to the transplant date which is consistent with Time 1
measurement period. The mean at Time 1 for this subscale was the highest mean on this
tool. PFS-R Total and subscale scores can be found in Table 7.
Table 7. PFS-R Total and Subscale Scores

Baseline
(n = 84)

M (SD)

Time 1
(n = 73)

M (SD)

Time 2
(n = 60)

M (SD)

Min
Max

Min
Max

Min
Max

PFS-R Total

Behavioral
Severity

Affective
Meaning

Sensory

Cognitive
Mood

3.58
(1.99)
0
7.68

3.35
(2.83)
0
8.83

3.48
(2.48)
0
8.40

4.28
(2.40)
0
8.20

3.20
(1.99)
0
9.00

4.19
(1.79)
0
9.00

4.08
(2.47)
0
9.33

3.82
(2.18)
0
8.80

5.05
(2.17)
0
9.40

3.80
(1.98)
0
9.50

4.13
(2.13)
0
8.59

3.82
(2.58)
0
9.66

4.12
(2.63)
0
8.80

4.82
(2.49)
0
9.20

3.88
(2.18)
0
9.33

Note. Time 1= Day 0-Day 2; Time 2 = Day 9-Day 11.
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Data analysis for aim 1. Aim 1 focused on demonstrating a relationship between
light exposure and mood and fatigue scores. There were no Light Measures at baseline.
The analysis for correlation also included KPS to evaluate whether there was any
significant correlation between it and the other tools. Light Time 1 measure significantly
correlated with Light Time 2. There was no correlation seen between Light Time 1 and
POMS-SF Total Time 1 (r=0.08, p=0.54), PFS-R Total Time 1 (r=0.07, p=0.54) or KPS
Time 1 (r=-0.14, p=0.34). There were no correlations seen between Light Time 2 and
POMS-SF Time 2 (r=0.05, p=0.72), PFS-R Time 2 (r=0.04, p=0.75) or KPS Time 2
(r=0.11, p=0.51). These results are displayed in Table 8.
There were no correlations found between any of the Light Measures Time 1 and
any of the Subscale score for the POM-SF Time 1, PFS-R Time 1 or for the KPS
completed on Day 2 of transplant. These data are shown in Table 9. There were no
correlations found between Light Measure Time 2 and any of the Subscale score for the
POM-SF Time 1, PFS-R Time 2 or for the KPS completed on Day 11 of transplant.
These data are shown in Table 10.
Data analysis for aim 2. Aim 2 for this study was to investigate the relationship
if any between light exposure and physical activity in the bone marrow transplant patient.
The assessment of physical activity was made by measurement of the number of steps the
participant took during the 48 hour periods of Day 0 to Day 2 (Steps Time 1) and Day 9
to Day 11 (Steps Time 2). The step data can be found in Table 11 and steps have been
calculated in the thousands. The means between Time 1 and Time 2 measurements were
very similar, as were the minimum and maximum readings.
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Table 8. Light Correlation with POMS-SF Total, PFS-R Total and KPS
Time1
Light Light
Time Time POMS PFS
1
2
Total Total KPS
Light r
Time p
1
n
Light r
Time p
2
n

0.33
0.02
52

0.08
0.54
67

Time 2
POMS PFS
Total Total KPS

0.07 -0.14
0.54 0.35
67
47

0.32
0.01
52

Note. Time 1= Day 0-Day 2; Time 2 = Day 9-Day 11.

0.05
0.725
55

0.04
0.75
55

0.11
0.51
38

Table 9. Light Correlations with POMS-SF & PFS-R Subscales at Time 1
POMS-SF Subscales – Time 1
TensionAnxiety
Light
Time 1

r
p
n

-0.05
0.68
67

DepressionDejection
0.11
0.36
67

AngerHostility
0.12
0.35
67

VigorActivity
-0.06
0.65
67

PFS Subscales – Time 1

FatigueInertia
0.05
0.70
67

ConfusionBewilderment
0.08
0.52
67

Behavioral
Severity
0.06
0.64
67

Affective
Meaning

Sensory

-0.02
0.89
67

-0.05
0.69
67

Cognitive
Mood
0.14
0.24
67

Note. Light Time 1 = Day 0-Day 2.
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Table 10. Light Correlations with POM-SF & PFS-R Subscales at Time 2
POMS-SF subscales – Time 2

Light
Time 2

r
p
n

PFS-R subscales – Time 2

TensionAnxiety

Depressiondejection

Angerhostility

Vigoractivity

Fatigueinertia

Confusionbewilderment

Behavioral
severity

Affective
meaning

Sensory

Cognitive
mood

0.043
0.75
55

-0.025
0.85
55

0.04
0.77
55

0.05
0.69
55

-0.07
0.60
55

0.05
0.71
55

-0.005
0.97
55

0.05
0.70
55

-0.03
0.81
55

0.09
0.53
55

Note. Light Time 2 = Day 9-Day 11.
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Table 11. Steps Data
Steps
(in thousands)

a

Time 1 (n = 69)

M (SD)
Min
Max

8.45 (4.17)a
1.44
16.90

Time 2 (n = 57)

M (SD)
Min
Max

7.26 (3.78)a
1.36
15.16

Cumulative steps for 48 hour period

Physical activity, as measured through number of steps taken, was not shown to
be correlated with levels of light exposure. Of note, there were significant fewer
participants for step calculations between Steps Time 1 (n=69) and Steps Time 2 (n=57).
This was due to participants dropping out of the study and to the couple of documented
equipment failures. These data can be seen in Table 12. A correlation was seen however
between Steps Time 1 and Steps Time 2. The number of steps taken during the first
measurement period was statistically significant to the number of steps the participant
took during the second measurement period (r = 0.50, p < 0.0001).
Table 12. Correlation between Light and Steps
Steps
Time 1
Light Time 1

r
p
n

Light Time 2

r
p
n

Steps
Time 2

-0.12
0.31
67
-0.00046
0.99740
55
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Aim 3 data analysis. The third aim of this study was to establish the relationship
between the level of light exposure and fatigue levels during the in hospital bone marrow
transplant experience.
The regression analysis for this aim is displayed in Table 13. Parameters for all
biomarkers at Time 2 (Age, Height, Baseline Weight, Gender, Diagnosis and Transplant
type) were added to the model and assessed for fit through stepwise backwards selection.
All parameters except for baseline PFS-R (and including Total Light) were forced out of
the model. Baseline PFS-R was shown to have a strong relationship to PSF-R at Time 2
(Estimate =0.72, SE = 0.12, P = 0.0001). At this time there is not enough evidence to
draw an association between fatigue at 11 days post-transplant, light, and these other
factors.
Table 13. Fatigue at Time 2, with Baseline Fatigue and Light Exposure as Covariates
Regression

Intercept
Light (in
thousands)
Baseline PFS-R

Parameter
Estimate (SE)

T

p

Variance
inflation

1.042(0.52)

2.01

0.05

0.00

0.00136(0.00130)

1.05

0.30

1.08

0.72(0.12)

6.15

0.0001

1.08

Note. n = 49.

Post hoc data analysis. The question of whether activity and light would be
significant predictors of mood, at time 1, was explored. A regression model using POMSF Total Time 1 with Light Time 1 and Steps Time 1 demonstrated that at Time 1, light
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was not show to have a significant effect on POMS-SF, while steps was a significant
predictor of total mood (p = 0.005). These results can be seen in Table 14.
Table 14. Coefficients with Light 1 and Steps 1 and Mood at Time 1
Unstandardized
coefficients
Model
1 Constant
Steps_1
Light_1

B
6.47
0.000
1.237E-6

Standardized
coefficients

SE

β

t

Sig

1.14
0.000
0.000

-.34
.03

5.690
-2.910
0.282

.000
.005
.780

Note. Dependent Variable: Mood, Time 1.

Similarly, the question of whether activity and light were predictors of fatigue, at
time 1, was explored. A regression model using PFS Total Time 1, with Light Time 1 and
Steps Time 1 demonstrated that at time 1, light was not show to have a significant effect
on PFS Total Time 1 while, similar to the results for mood, the number of steps was a
significant predictor of fatigue (p = 0.010). Patients who engaged in more activity had
lower levels of fatigue. These results can be seen in Table 15.
Table 15. Coefficients with Light 1 and Steps 1 and Fatigue, Time 1
Unstandardized
coefficients

Standardized
coefficients

Model

B

SE

β

1 Constant
Steps_1
Light_1

5.38
0.000
5.99E-7

.55
.00
.00

-.34
.03

t
9.71
-2.84
0.28

Sig
.000
.010
.780

Note. Dependent Variable: Total Fatigue, Time 1.

Similar to the results for time 1, a regression model for mood at Time 2
demonstrated that light did not have a significant effect on POMS-SF Time 2, while steps
continued to be a predictor of mood (p = 0.030). These results are shown in Table 16.
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Table 16. Coefficients with Light 2 and Steps 2 and Mood, Time 2
Unstandardized
coefficients

Standardized
coefficients

Model

B

SE

β

t

Sig

1 Constant
Steps_2
Light_2

6.0
0.00
-1.923E-6

1.27
0.00
0.00

-.30
.06

4.70
-2.27
-0.47

.000
.030
.640

Note. Dependent Variable: Mood, Time 2.

Finally, similar to the results for Time 1, a regression model using Total fatigue at
Time 2, with the independent variables of Light at Time 2 and Steps at Time 2
demonstrated that light was not shown to have a significant effect on total fatigue at Time
2, and steps was no longer a significant predictor of total fatigue (p = 0.14). These results
can be seen in Table 17.
Table 17. Coefficients with Light 2 and Steps 2 and PFS TFS 2
Unstandardized
coefficients
Model
1 Constant
Steps_2
Light_2

B
4.89
0.00
7.051E-6

Standardized
coefficients

SE

β

t

Sig

.71
.00
.00

2.20
0.04

6.85
-1.48
0.31

.000
.140
.760

Note. Dependent Variable: PFS_TFS, Time 2.

Further exploratory analyses were undertaken with the subscales of the POMS
and PFS, with no change in the pattern of findings. These findings should be viewed with
caution. Considering the number of analyses completed and the possibility of an inflated
Type I error rate, light was not a significant predictor of any dimensions of fatigue or
mood.
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In summary, the sample was predominantly male, Caucasian and was receiving a
BMT for multiple myeloma, lymphoma or AML. The KPS showed minimal change at
the three assessment time points and did not have any correlation to light exposure.
Scores on the PFS-R demonstrated predominantly moderate fatigue levels. There were no
correlations found between Light and measures for fatigue, mood or activity. In post hoc
analysis, there were identified correlations between steps and mood at Time 1 and 2 and
steps and fatigue at Time 1. The following chapter will discuss the findings from this
study, the implications for nursing science and thoughts on future research directions.

CHAPTER FIVE
DISCUSSION
The purpose of this exploratory study was to determine whether there is a
relationship between natural and ambient light exposure and the hospitalized bone
marrow transplant patient’s perceived state of mood and fatigue. A second aim was to
evaluate the relationship between the bone marrow transplant patient’s exposure to light
and the patient’s physical activity at two time points during the hospitalization. The aims
of this research were achieved, however the findings were not of the magnitude expected.
While the relationship between light exposure and the dependent variables of mood,
fatigue and activity was not exposed, a relationship between activity, mood and fatigue
was identified in the data. Regardless, the findings do provide valuable information for
current knowledge and future studies. In this chapter, the overall characteristics of the
sample will be discussed in addition to the study’s aims and the summary of findings.
The limitations of this study, the implications for the profession of nursing and
recommendations for future research are also provided.
Characteristics of the Overall Sample
As previously discussed in the results chapter, the majority of the sample were
male, Caucasian and age 60 and over. The sample lacked substantial diversity with only
eight Latinos, four African Americans and 28 females participating in the study. The site
of the study is a suburban area, which is very racially diverse however it would not
116
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appear that the patient population being served reflects this. The availability of Hispanic
participants was larger, however a language barrier prevented enrollment with some
patients not possessing a level of English proficiency which would allow them to
understand the verbal explanation of the study or the reading and comprehension of the
consent document. In addition, there were no interpreters available to interact with the
investigator in attempting to recruit this subset of patients. With the lack of diversity in
the sample, it is unknown whether the results could have been different with a more
diverse sample.
A multiple myeloma diagnosis constituted a third of the participants for the study
(n = 29, 32.9%) with lymphomas and leukemia representing the remainder of the
participants with one exception of myelodysplastic syndrome. Multiple myeloma is
typically a malignancy seen in older populations while lymphomas and leukemias affect
all age groups. The present treatment approach for multiple myeloma begins with
chemotherapy as the initial treatment. This treatment has the opportunity to keep the
disease “at bay” for multiple years. Bone marrow transplant is not the initial treatment
approach for multiple myeloma but will be considered when the patient demonstrates
progression after multiple regimens.
Lymphomas and leukemias both have multiple sub-categories with cell types
reacting differently in the disease trajectory and resilience against treatment response.
Both of these malignancies contain subcategories where treatment with chemotherapy
plus or minus radiation can be effective in disease remission; however, both have
subcategories of very aggressive disease courses requiring chemotherapy, radiation and
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ultimately bone marrow transplantation. The variability in the underlying diagnosis and
disease/treatment histories for the participants in the study created a sample that may lack
satisfactory and significant homogeneity. That being said, examining for any correlations
within the variables by diagnosis type did not yield any further information.
Autologous transplant was used in over 60% of the participants. The post
transplant trajectory can be different for autologous versus allogeneic transplants. Since
the cells providing the allogeneic transplant are not coming from the patient, this type of
transplant may encounter more GVHD which can dramatically change the post transplant
recovery. Post hoc testing for correlations between the variables delineated by the type of
transplant did not yield any significant findings. Given a larger sample size, differences
may have been found between malignancy types, treatment histories, and type of
transplant.
There was an intentional rationale for not collecting demographic data involving
occupation, median income, or family information. The transplant process is a long one
so most of these participants would not be actively employed; occupation and income
were judged as not relevant to the study aims. All the participants had to have some type
of family or friend support in order to complete the post discharge transplant requirement
so collecting family information was not deemed relevant.
In planning this research, a power analysis projected the need to enroll 82
patients. With the investigator’s estimate of a 10% attrition rate, the sample size was
increased to 90 patients. In reality, the study experienced more than a 30% attrition rate
yielding a final sample size of 60 patients with completed measures. Many of the studies
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discussed in the second chapter of this paper had very small sample sizes yet they
demonstrated statistical significance in their findings. Sixty participants should have
provided sufficient numbers to reveal any associations, however, this was not seen in the
results.
The significant number of patients who withdrew from the study due to feeling
unwell may have provided more extreme values in the measures had they continued to
participate. If the patients that remained in the study were more ‘healthy’ than those who
declined to continue, it could be expected that they had lower mood disturbance and/or
fatigue. Those patients who withdrew from the study may have contributed much
different data had they continued. Those who felt well enough to continue may have had
a more positive mood, less fatigue and/or greater activity. There is no way to know how
different the findings would have been had the attrition rate truly been only 10%. A
study with a much larger sample size may provide more insight.
This investigator was acutely aware of the difficult treatment regimens these
patients undergo. With substantial mortality rates associated with BMT, the treatments
and resulting BMT can tax the participant in almost every aspect of their lives. At any
time, if the patient stated they did not feel up to participating in that data collection point,
their decision was accepted immediately. If there was a future data collection point, the
patient would be asked if they could be approached for that activity. Having worked in
clinical trials for many years, the value of the participant’s consent along with their
ability to retract that consent at any time was forefront in the investigator’s mind. This
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could have impacted the attrition rate; however, even a captive audience should have the
ability to leave at any time.
Discussion of Aims
Discussion of aim 1. The primary goal for this study was to determine whether
there is a relationship between light and a BMT patient’s perceived mood state and
fatigue level. The literature reviewed in preparation for this study indicated that mild
fatigue level scores would be present in both autologous and allogeneic patients at the
beginning of the transplant process. For example, previous findings demonstrated by Day
5 post transplant, 90% of the patients would score themselves with moderate to severe
fatigue (Danaher-Hacker et al. 2006). Another study found a high correlation between
fatigue scores and those of anxiety and depression during the transplant process
(Molassiotis, 1999). Findings from this present study demonstrated fairly stable fatigue
levels over time from Day 0 to Day 11. There were no dramatic shifts observed in the
means for the PFS-R or POMS-SF Totals or subscales at any of the measurement points.
All measures on these two instruments indicated that patients in this study were in the
upper limit of mild symptoms to the middle limits for moderate symptoms. This study’s
findings were not consistent with present literature. As stated earlier, patients who
completed the trial could have constituted the healthier patient group when compared to
those who withdrew.
The lack of findings in any correlation between light exposure, fatigue and mood
at Time 1 or Time 2 was disappointing, particularly because it does not appear to be in
line with previous studies. While a 30% drop out rate may be indicted as a possible case
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for the lack of correlation, it is unknown whether a larger sample size would have
revealed different results.
In the self-administered tools, there were instances when the tools were only
partially completed by the patient. In these cases, if the patient was still in the hospital,
the investigator would work with the subject in completing the instrument. There were
instances where the patient was discharged prior to day 11 and prior to the investigator
meeting with the patient. Failure to have the entire tool completed may have impacted
study findings. In addition, having the investigator assist the patient with the completion
of the tool may have affected the way the patient responded to the questions.
It was frequently noted that patients who were obviously experiencing a
tremendous amount of fatigue ranked themselves “lively” or “active” when completing
the PFS-R. Patients may have been projecting how they would like to feel rather than
giving a score that truly reflected the amount of distress the fatigue was causing them.
While the majority of the patients were not on any anti-depressant medications, there
were medications which may have affected the patient response on the instrument.
Narcotics and anti-anxiety medications could make the patient feel tired which would
predispose them to completing the instrument with more or less fatigue or mood change.
It is again important to note that studies discussed in Chapter 2 had much greater fatigue
and mood distress in transplant patients than seen in this present study.
Nightingale (1859/1960) spoke of sunlight as being beneficial to patient recovery
in a time of limited availability of ambient lighting devices. Within this study design,
there was no differentiation in the type of light the patient received. Not being able to
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quantify the level of natural lighting versus artificial lighting the patients received may
have assisted in further explanations for the measured variables.
Finally, data on light levels had to be impacted by how the device was worn by
the patient. While patients were coached to keep the wrist wearing the device outside of
bed linens and robes, compliance with this was frequently found an issue. Finding the
patients ambulating in the hall with robes on or resting in their bed under linens, the wrist
device was frequently found to be covered. This would definitely impact the devices
ability to correctly record light levels. In addition, patients would be removing the
devices for twice daily tub baths. The duration of time the device was off of the patient
was not captured. This time interval could vary greatly between patients; some patients
admitted forgetting to re-apply the wrist device in a timely fashion after bathing. Because
it was impossible for the investigator to be present all the time to address this with
participants, this could not be controlled for and could definitely impact the light
exposure data. Possibly placing the light meter on the intravenous pole for the 48 hours
would have provided more accurate data.
Discussion of aim 2. The second aim of the study was to establish a relationship
between the light level exposures and the physical activity of the patient. The mean for
Step Time 1 was higher than Step Time 2 mean however these two measures were
moderately correlated with one another (.50, p = <.0001). This could mean that activity
between the 2 time points did have a relationship and patients were consistent with their
activity between those time intervals. This finding was unexpected considering patients
receiving the transplant on Day 0 typically have very little activity on that day. For that
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reason, one could assume that Step Time 2 measure would be higher. It also would be
impossible to project how the attrition rate between these two measurement points
impacted the statistics. Other than this correlation, this study did not find any relations
between light exposure and the steps taken for either Time 1 or Time 2 measurement
periods.
The KPS score mean for Time 1 measure was very similar to Time 2 measure.
Theoretically, a decline in the patient’s KPS score could be associated with the patient’s
activity. There was an identified problem with the measurement of this variable because
its documentation by physicians in the medical record was inconsistent. Even though
KPS is not an activity scale but addresses functional performance, a correlation between
KPS and Light Time 1 and 2 was performed. No correlation found between the KPS
measures and these 2 light measurement periods.
Similar to the discussion of Aim #1 regarding light meter placement, there was an
issue with how the activity monitor was worn by the participant. While the measurement
by the Actical was not impacted by robes or bed sheets, the data from it may have been
impacted similar to the Actiwtach in the length of time the device was off of the patient
during the twice daily tub baths. It is not known exact time intervals when activity may
not have been recorded during that 48 hours period. While both devices are water
resistant, they were not water proof so full submersion for a short length of time would
render them non-functional. As it were, at least one patient forgot to remove the devices
during a bath causing the devices to stop working. The devices were returned to the
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manufacturer who unsuccessfully attempted data retrieval and the devices were deemed
permanently inoperable.
Patients were coached to apply the Actical on the same wrist throughout the 48
hour time period and were asked to push their IV pole with the hand opposite from the
wrist of the Actical placement. It was felt that the free swinging of the arm would
facilitate more accurate activity measure. But patients were frequently found ambulating
without being compliant of this request. With all the interventions the patient is
experiencing, their inability to remember instructions is not surprising. Alternatively, the
placement of the Actical could have been around the patient’s waist or on the patient’s
ankle. These locations were not selected for two reasons. Waist placement was avoided
because it was felt that the device might be easily lost with changing gowns frequently
due to the twice daily tub baths. Ankle placement was not possible for all patients due
frequent lower leg and feet swelling. A majority of the participants experienced this side
effect, making ankle placement not consistently possible for all patients.
While the light exposure means for Day 0-2 and Day 9-11 were not grossly
different, the Time 2 mean was slightly higher (113.39 lux versus 127.28 lux
respectively). This could be expected. As the transplant engrafts, the blood counts slowly
rise. Given this increase in hemoglobin and hematocrit, increased activity tolerance
would be expected as the patient progresses post transplant. There was a correlation
between Light Time 1 and Light Time 2; the amount of light exposure at Time 1 could be
a predictor of light exposure for Time 2. However logic would say that greater light
exposure occurs in the hallway and the hallway is associated with patient activity.
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However, this logic was not held by the statistics. Light exposure did not have any
correlation of step data at either one of the time intervals.
Discussion of aim 3. For the third aim, the study intended to determine whether
there was a relationship between light exposure and fatigue. A regression model utilized
PFS-R at baseline plus total measure of light plus any error equaling PFS-R Time 2. The
cumulative measure of light was not found to be significant to the remainder of the
model. The model shows that for every increase in the baseline of PFS-R, there was an
increase of 0.7 in the scoring of PFS-R Total Time 2. This was not supported by the
model. Similar to the discussion of aim #1, it is unknown whether a larger sample size
would have provided different findings.
Discussion of post hoc analysis. While light exposure was not significantly
associated with mood, fatigue or activity, the post hoc analysis demonstrated that steps
might be the primary predictor for mood and fatigue for this patient population during the
transplant hospitalization period. This is an important finding which demonstrates the
benefit for these patients to push themselves toward greater activity during the acute
transplant phase. The patient’s ability to gain an improved mood state alone is a reason to
get the patient up and walking outside of their hospital room.
Study Limitations
This study was exploratory and utilized a convenience sample. This design was
appropriate for examining any relations between the variables, absent any intervention.
The study did not have adequate ethnic or racial diversity and was hindered by not having
Spanish literature, consent and interpreters available for recruitment. While the study site
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was located in a racially diverse suburb, opening up the study as a multi-institutional
study may have provided a better participant pool. Providing translated materials and
interpreters would definitely have impacted recruitment for Hispanic patients.
As discussed previously, the participants of this study had multiple types of
malignancies. The differences in disease characteristics, duration of illness, prior
treatment regimens, type of transplant and time to transplant create a participant pool that
may not have been similar enough. The disease details may be worthy of a secondary
analysis looking for relationship of variables in subcategories. The only elements which
were evaluated statistically were those of diagnosis and transplant time; this analysis did
not support any relevant findings.
While the power analysis performed pre-study determined patient accrual of 82 as
adequate, the attrition rate within the 90 participants was 30%. This rate is definitely
impacted by the nature of the underlying cancer diagnosis and the severity of the
treatment. Participants who initially seemed enthusiastic in participating prior to
hospitalization had no way of anticipating how unwell they may feel once admitted and
treatment is initiated. Increasing accrual would be appropriate given this experience with
attrition in this patient population.
The question of an underpowered study should be considered. A post hoc power
analysis uses the observed, rather than the predicted correlation. In planning the study, an
estimate of effect size, along with a planned alpha level of .05 for hypothesis testing, and
a power of .80 were used. After the study, in post-hoc power analyses, all results obtained
were underpowered, based on the effect sizes obtained. An adequately powered study
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should have included a larger number of patients to achieve a higher percentage of
complete data sets. The central problem with doing a post hoc power analysis is that it
implies a conclusion that if the study had encountered the full number of necessary
patients with completed data sets, a difference would have been found. However, in
reality, one can never know what the additional patient data sets would look like. Either
way, the conclusion is the same; the study was impacted by significant participant
attrition with a smaller than anticipated effect size. As noted earlier in this discussion, it
can not be projected how different the data would have looked had the attrition rate been
lower and more of the patients who felt unwell had chosen to continue.
A limitation to the study may be the lack of control regarding the wearing of the
data collection devices. It has already been discussed that the taking of devices on and off
as well as not wearing the devices appropriately may have impacted the data obtained in
this study. Had the investigator been on site more, possibly better control may have been
achieved in how the devices were worn.
Using paper instruments to measure variables can be challenging. For the patient
who does not feel well, the instrument may not be completed, the patient ‘circles
anything’ to complete it, or they select responses based on how they would like to feel
rather than their current state. Interventions may impact the patient responses such as
medications being administered or blood transfusion causing distress. That being said, it
is an accepted way of collecting patient feelings; it just may be more challenging with a
patient population as sick as the BMT patient.
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Implications for Nursing
Nursing has always been interested in how the patient interacts and adapts to the
environment, in sickness and in health. As a profession, Nursing has been ready and
willing to investigate non-medical interventions in the endeavor to help a patient recover
to a pre-illness state. Nightingale (1859/1960) was on the forefront of understanding that
some elements in the environment were harmful to the patient, while recognizing that
some truly made a difference in recovery. She recognized light and fresh air as beneficial
to patients at a time when light was scarce and air was foul. While this research was not
able to identify the exact correlations, there are a plethora of research that has done just
that. Nursing needs to continue this endeavor because these elements of the environment
are interventions that we can educate our patients on, help our patients apply, and monitor
patient for their response.
Roger’s (1970) Science of Unitary Human Beings uses the same idea, however
ramps it up to true theoretical status. But the underlying concepts and interactions are
under the same perspective as Nightingale (1859). From all we know at the present, we
can say with certainty, the person is continually interacting with their environment.
Whether it is light coming in the window or pollution coming from the air, the human is
interacting with this. We know that environmental elements cause illness and that light
can facilitate healing. We also know that through this interaction, the person changes in
some way. Within Rogers’ theory, light is part of the environmental energy field that the
patient’s energy field interacts with on a continual basis. The underlying disease process
of cancer as well as the BMT treatment process are internal stimuli that impact the
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patient’s energy field. Those internal stimuli should be able to change the patient’s
patterning just as the interaction between patient and environmental light can induce
changes.
This study did not demonstrate that higher light exposure could decrease fatigue,
make the mood better or help the patient’s activity increase. But because of the work in
psychoneuroimmunology and circadian rhythms, we know that there is a connection
between the physiologic functioning of the body and mind with that of light. We also
know that inflammation associated with cancer diagnosis and treatment is associated with
biochemical functions in the body. The significant finding in the correlation of number of
steps with mood state and fatigue does support that interacting with our environment
(through activity) may be a predictor for mood state and fatigue levels. The underpinning
of this idea again supports Roger’s model.
While we know the runners attain a boost in mood with running, we are just
beginning to examine what activity can do for the person fighting against a serious
disease. BMT patients are aware of the activity requirements which are part of the
treatment plan. In our education of these patients, we need to help them make that
connection. The benefits of activity are not only to prevent pulmonary complications
associated with bedrest; the activity is going to make them feel better.
A nurse is continually educating people toward achieving better states of health
and wellness. Certainly the research on how the body interacts with the environment is
one that nursing should be sharing. But as an active participant, the patient needs to
understand the disease as a stimulus so they can understand what they must do to impact
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the outcome of the treatment process. Consistent with Rogers (1970), allowing the patient
to participate in this research may have assisted them in addressing the changes that were
evolving within themselves. The patient could attempt to receive the maximum amount
of light and perform the maximum amount of activity in an attempt to increase the
amount and type of patterning as they respond to their illness. This approach of
maximum light and activity would be an area for further study. Nursing has the ability to
work with patients undergoing BMT coaching them toward higher activity and maximum
light exposure as an intervention in the plan of care. This is within the scope of nursing
practice.
BLT can be viewed as a non-invasive intervention that has a positive effect on
certain patient populations. As a non-invasive intervention, it should be within the realm
of nursing to use it with patients who may benefit from it. The negative side effects are
minimal. Commercially available bright light lamps are available without a prescription.
The problem does still exist that we do not have a standard of care for the time of day for
delivery, the frequency and the dosing of how much BLT is needed for any particular
patient. This is why BLT should be an intervention that nursing is excited about
investigating in more diverse patient populations. While this research may not illuminate
the exact mechanisms of its benefit for the patient, BLT holds a promise in improving
patient lives and experiences.
Suggestions for Future Research
Certainly more research needs to be done on patient response to light exposure
and BL therapy. Much is still unknown in how and why it works for certain patient
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populations such as those with neurodegenerative disease. BLT has a potential role of
interacting with the body at a cellular level making biological and pathophysiological
changes that are not understood. Designing a study which would include the application
of different BLT dosages and different treatment times and time intervals might be a
good starting point. The literature does not provide enough scientific evidence on any of
these criteria. This type of study would add much to the body of knowledge on BLT.
As we continue to understand more about psychoneuroimmunology, the idea that
light has an effect on that system is accepted. If the patient has lost their immune system
through the BMT process, is the pathway for beneficial effects of light on the body
somehow disrupted? Light exposure may not ‘work’ in the patient who has lost a critical
part of that psychoneuroimmunology system. Possibly looking at a patient with a similar
hospital stay without an immune aberration compared to the hospitalized BMT patient
would better illuminate that question.
In summary, this exploratory study did not achieve its original aims. However, it
demonstrates that there is much more investigation that needs to be completed to truly
understand the relationship of light and other factors in the transplant patient. The
findings may inspire others to perform more research on light application to this patient
population. The information shared here will benefit the next researcher interested in
pursuing the idea that light may be a good intervention for the hospitalized BMT patient.
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IRB NUMBER: 204782101712
LOYOLA UNIVERSITY CHICAGO
HEALTH SCIENCES DIVISION
MAYWOOD, ILLINOIS
INFORMED CONSENT
Participant’s Name: _____________________________________________________
Medical Record Number: _________________________________________________
Title of Study: The Relationship between Light Exposure and Fatigue and Mood in the
Patient Undergoing Bone Marrow Transplant

THE APPROVAL FOR THIS PROJECT EXPIRES ON 07/24/2015.

Participant Information
Principles concerning research. You are being asked to take part in a research
study. It is important that you read and understand the principles that apply to all
individuals who agree to participate in the research project described below:
1. Taking part in the research is entirely voluntary.
2. You will not benefit from taking part in the research but the knowledge
obtained may help others.
3. You may withdraw from the study at any time without anyone objecting and
without penalty or loss of any benefits to which you are otherwise entitled.
The purpose of the research, how it is to be done and what your part in the
research will be is described below. Also described are the risks, inconveniences,
discomfort and other important information, which you need to make a decision about
whether or not you wish to participate. You are urged to discuss any questions you have
about this research with the staff members.
Purpose of research. You are being asked to participate in this study because you
are undergoing a bone marrow transplant.
The purpose of this study is to investigate the relationship between light exposure
and the perception of fatigue and mood during the bone marrow transplant procedure.
This research will also evaluate levels of physical activity and sleep/wake intervals in
relationship to light exposure.
This research is for a doctoral dissertation, a graduate school project being done by Kim
Anderson-Drevs.
Approximately 90 people will participate in this research.
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Description and explanation of procedures. If you agree to participate in the
study, you will be asked to sign this informed consent document once the study has been
explained to you. Prior to hospitalization or prior to your chemotherapy starting, you will
be asked to complete two surveys providing information about your fatigue and your
mood. On Day 0 of your transplant, you will be asked to wear a small light meter and
activity monitor on your wrist which measure the amount of light you receive, your sleep
and your activity over a 48 hour period. At the end of the 48 hour period, you will be
asked to complete the 2 surveys regarding fatigue and mood again. This process will be
repeated at Day 9 of your transplant; wearing the wrist band for 48 hours and completing
the 2 surveys at the end of the 48 hour period.
Risk/discomforts. There no treatment component in this study. It is not
anticipated that participation will result in any risk or discomfort.
Benefits. You will not benefit from participating in this study.
Alternative. You do not have to participate in this research project to receive care
and treatment at Loyola University Medical Center.
Financial information. There is no cost associated with your participation in this
study. Neither you nor your insurance provider will be billed for any procedures that are
performed exclusively for this research study. Those procedures that are being performed
for research purposes only include the completion of surveys and monitoring light and
activity with devices.
Research related injury. In the event that you are injured as a result of
participating in this research project, your doctor will take the necessary steps to treat the
problem. There are no funds available from Loyola University Medical Center to pay for
the cost of care of the problem. You will be financially responsible for the cost of care of
any problems.
Information collected and what will happen to it. In order to meet the goals of
the research study, we will collect information on you, your survey results and how you
do. The information will be collected by Kim Anderson-Drevs. In this collection, we will
learn about the relationship between light levels and a patient’s perception of fatigue and
mood during hospitalization.
The information we will collect includes:
__X__ DEMOGRAPHIC INFORMATION (E.G. NAME, ADDRESS, PHONE
NUMBER, MEDICAL RECORD NUMBER
__X___MEDICAL RECORDS (INCLUDING BUT NOT LIMITED TO, HISTORY
AND PHYSICAL EXAM NOTES, PROGRESS NOTES, CONSULTATION
REPORTS, LABORATORY TEST RESULTS AND/OR OPERATIVE REPORTS)
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We will collect information about you for as long as you are in the study which is
considered up to 16 days after your transplant.
The results of is research study may be published in a journal for the purposes of
advancing nursing knowledge. You will not be identified by name or by other identifying
information in any publication or report about this research.
Withdrawal of consent. Your consent to use and disclose your medical
information for this research study is completely voluntary. You can withdraw your
consent for LUMC to use and disclose your information and your consent to participate
in this study at any time without affecting your ability to receive care and treatment at
LUMC unrelated to the research study. Withdrawal means that all study procedures and
follow up will stop.
If you withdraw from the study, we will ask that you sign the form attached to this
consent and send it to:
Kim Anderson-Drevs
1408 W. Taylor Street
#401
Chicago, IL 60607
(708) 212-5558
Your withdrawal from the study will not have any effect on any actions by LUMC
taken before the attached form is received.
Your study doctor and the Institutional Review Board, regulatory authorities or the
principle investigator may terminate the study at any time with or without your consent.
Your doctor may choose to take you out of the study.
CONSENT
I have fully explained to ___________________________ the nature and purpose
of the above described procedures and any risks that are involved in its performance. I
have answered and will answer all questions to the best of my ability. If you have any
questions about this study, you should contact Kim Anderson-Drevs at (708) 212-5558 or
Lee Schmidt, PhD, chairman of the dissertation committee at (708) 216-3573.
_______________________________________ ___________________
Signature Date
If you ever feel that you have been injured by participating in this study or if you
have any questions concerning your rights as a research participant, you may contact
either Kenneth Micetich, MD, Chair of the Institutional Review Board for the Protection
of Human Subjects-Loyola University Chicago Health Science Division at 708-216-2633
or Elaine Fluder, MSN, Director of the Human Research Subject Protection Program at
708-216-4608.
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Although you have the right to revoke this authorization, you accept that such
revocation will not apply to any uses and disclosures of your information that are
described in the Loyola University Health System Notice of Privacy or otherwise
allowable under any Federal or State laws.
You will receive a signed copy of this informed consent document.
You have been fully informed of the above described research program with its
possible benefits and risks. Your signature below indicates that you are willing to
participate in this research study and agree to use and disclosure of information about you
as described above. You do not give up any of your legal rights by signing this consent
document.
_______________________________________ ___________________
Signature: Participant Date
_______________________________________ ___________________
Signature: Witness Date
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PROJECT TITLE: The Relationship between Light Exposure and Fatigue and
Mood in the Patient Undergoing Bone Marrow Transplant
REVOCATION OF AUTHORIZATION
TO RELEASE PROTECTED HEALTH INFORMATION (PHI)
I, _______________________________________, hereby revoke my consent to
participate in the research, The Relationship Between Light Exposure and Fatigue and
Mood in the Patient Undergoing Bone Marrow Transplant at Loyola University Medical
Center (LUMC). I also revoke my consent to release information I provided to LUMC
that allowed LUMC to use and disclose my medical information to the principle
investigator listed as outlined on the consent form, which I signed on ____________. I
understand that this revocation does not apply to any action LUMC has taken in reliance
on the consent I signed earlier.
_______________________________________ ___________________
Signature: Participant Date
Please return this form to:
Kim Anderson-Drevs
1408 W. Taylor Street
#401
Chicago, IL 60607
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THE PIPER FATIGUE SCALE
Patient ID no.______
Directions: For each of the following questions, circle the number which best describes
the fatigue you are experiencing now. Please make every effort to answer each question
to the best of your ability.
1. How long have you been feeling fatigued
a. ___________ minutes
b. ___________ hours
c. ___________ days
d. ___________ weeks
e. ___________ months
f. ___________ other (please describe): __________________________
2. To what degree is the fatigue you are feeling causing you distress?
No distress
0
1

2

3

4

5

6

7

A great deal of stress
8
9
10

3. To what degree is the fatigue you are feeling interfering with your ability to complete
your work or school activities?
None
0
4.

1

2

3

4

5

6

7

8

A great deal
9
10

To what degree is the fatigue you are feeling interfering with your ability to visit or
socialize with your friends?

None
0

1

2

3

4

5

6

7

8

A great deal
9
10

5. To what degree is the fatigue you are feeling interfering with your ability to engage in
sexual activity?
None
0

1

2

3

4

5

6

7

8

A great deal
9
10

6. Overall, how much is the fatigue which you are experiencing now interfering with
your ability to engage in the kind of activities you enjoy doing?
None
0

1

2

3

4

5

6

7

8

A great deal
9
10
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7. How would you describe the degree of intensity or severity of the fatigue which you
are experiencing now?
Mild
0

1

2

3

4

5

6

7

8

9

Severe
10

To what degree would you describe the fatigue which you are experiencing now as
being:
8.
Pleasant
0

1

9.
Agreeable
0
1

2

2

3

3

4

4

5

5

6

6

7

7

Unpleasant
10

8

9

8

Disagreeable
9
10

10.
Protective
0
1

2

3

4

5

6

7

8

Destructive
9
10

11.
Positive
0

1

2

3

4

5

6

7

8

9

Negative
10

12.
Normal
0

1

2

3

4

5

6

7

8

9

Abnormal
10

4

5

6

7

8

9

Weak
10

9

Alert
10

9

Listless
10

To what degree are now feeling?
13.
Strong
0
14.
Awake
0
15.
Lively
0

1

1

1

2

2

2

3

3

3

4

4

5

5

6

6

7

7

8

8
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16.
Refreshed
0
1
17.
Energetic
0
1

2

2

3

3

4

4

5

5

6

6

7

7

Tired
10

8

9

8

Unenergetic
9
10

18.
Patient
0

1

2

3

4

5

6

7

8

Impatient
9
10

19.
Relaxed
0

1

2

3

4

5

6

7

8

9

Intense
10

20.
Exhilarated
0
1

2

3

4

5

6

7

8

9

Depressed
10

21.
Able to concentrate
0
1
2

3

4

5

6

7

Unable to concentrate
8
9
10

7

Unable to remember
8
9
10

7

Unable to think clearly
8
9
10

22.
Able to remember
0
1
2
23.
Able to think clearly
0
1
2

3

3

4

4

5

5

6

6

24. Overall, what do you believe is most directly contributing to or causing your fatigue?
25. Overall, the best thing you have found to relieve your fatigue is:
26. Is there anything else you would like to add that would describe your fatigue better to
us?
27. Have you experienced any other symptoms this week?
No ________
Yes________ Please describe:
Copyright 1984 B. F. Piper
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Piper Fatigue Scale-Revised Scoring and Survey Results
1. The PFS-R in its current form is composed of 22 numerically scaled, “0” to “10”
items that measure four dimensions of subjective fatigue: Behavioral/severity (6
items #2-7); affective meaning (5 items: #8-12); sensory (5 items: #13-17; and
cognitive/mood (6 items: #18-23). These 22 items are used to calculate the four
sub-scale/dimensional scores and the total fatigue scores.
2. Five additional items (#13 and #24-27) are not used to calculate subscale or total
fatigue scores but are recommended to be kept on the scale as these items furnish
rich, qualitative data. Item #1, in particular gives a categorical way in which to
assess the duration of the respondent’s fatigue.
3. To score the PFS-R, add the items contained on each specific subscale together
and divide by the number of items on that subscale. This will give you a subscale
score that remains on the same “0” to “10” numeric scale. Should you have
missing item data, and the respondent has answered at least 75%-80% of the
remaining items on that particular subscale, calculate the subscale mean score
based on the number of items answered, and substitute that mean value for the
missing item score (mean-item substitution).
4. Recalculate the subscale score. To calculate the total fatigue score, add the 22
items scores together and divide by 22 in order to keep the score on the same
numeric “0” to “10” scale.
Severity Codes:
0
NONE
1-3 MILD
4-6 MODERATE
7-10 SEVERE

APPENDIX C
PROFILES OF MOOD STATES-SHORT FORM
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Below is a list of words that describe feelings people have. Please read each one
carefully. Then circle ONE answer to the right, which best describes HOW YOU HAVE
BEEN FEELING DURING THE PAST 24 HOURS.
The numbers refer to these phrases:
0= not at all
1= a little
2 = moderately
3 = moderate
4 = extremely
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.

Tense
Angry
Worn out
Unhappy
Lively
Confused
Peeved
Sad
Active
On edge
Grouchy
Blue
Energetic
Hopeless
Uneasy
Restless
Unable to
concentrate
18. Fatigued
19. Annoyed

1.

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

0 1 2 3 4
0 1 2 3 4

20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.

Discouraged
Resentful
Nervous
Miserable
Cheerful
Bitter
Exhausted
Anxious
Helpless
Weary
Bewildered
Furious
Full of pep
Worthless
Forgetful
Vigorous
Uncertain
about things
37. Bushed

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

0 1 2 3 4
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Scoring Instructions for the POMS-SF
Items by subscale
Tension-Anxiety: 1, 10, 15, 16, 22. 27
Depression-Dejection: 4, 8, 12, 14, 20, 23, 28, 33
Anger-Hostility: 2, 7, 11, 19, 21, 25, 31
Vigor-Activity: 5, 9, 13, 24, 32, 35
Fatigue-Inertia: 3, 18, 26, 29, 37
Confusion-Bewilderment: 6, 17, 30, 36, 34
Likert scores for each item in the subscale are added and divided by the number of items
in the subscale. This renders a sub-scale score. For the Total Mood Score (TMD), all subscale scores are added together with the exception of the Vigor-Activity score which is
subtracted from the total.
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KARNOFSKY PERFORMANCE STATUS SCALE
Able to carry on normal
100
Normal; no complaints; no
activity and to work, no
evidence of disease
special care needed
90
Able to carry on normal activity;
minor signs or symptoms of
disease
80
Normal activity with efforts;
some signs or symptoms of
disease
Unable to work; able to
70
Cares for self; unable to carry on
live at home and care
normal activity or to do active
for most personal
work
needs; varying amount
60
Requires occasional assistance,
of assistance may be
but is able to care for most of
needed
personal needs
50
Requires considerable assistance
and frequent medical care
Unable to care for self;
40
Disabled; requires special care
requires equivalent of
and assistance
institutional or hospital
30
Severely disabled; hospital
care; diseases may be
admission is indicated although
progressing rapidly
death is not imminent
20
Very sick; hospital admission
necessary; active supportive
treatment necessary
10
Moribund; fatal processes
progressing rapidly
0
Dead
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